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Cellulære og molekylære mekanismer ved metylkvikksølvindusert nevrotoksisitet  
Kvikksølv er et metall kjent og brukt til mange forskjellige formål i flere hundre år. Kvikksølv inngår i 
mange kjemiske forbindelser og på 1950-tallet ble det vist at en organisk form for kvikksølv, 
metylkvikksølv (MeHg), er nevrotoksisk. Til tross for omfattende forskning kjenner vi fortsatt ikke den 
molekylære mekanismen som ligger bak MeHg’s giftighet. MeHg reagerer med thiol-grupper og disse 
er vesentlige for enzymers normale funksjon. På denne måten kan MeHg skade de fleste enzymer i det 
cellulære maskineriet. MeHg’s giftvirkningen skyldes trolig et multippel av effekter på flere cellulære 
prosesser.
En av de viktige mekanismer bak MeHg-indusert giftighet er dannelse av reaktive oksygen radikaler 
(ROS) og reduksjon av mengden av glutation (GSH) i celler. Balansen mellom de antioksidante og 
reduktive prosesser er viktig for MeHg-indusert nevrotoksisitet. Cellekultursystemer er mindre 
komplekse enn hjernen og ble brukt som modell for å studere forandringene i slike cellulære prosesser 
etter MeHg-eksponering. MeHg-indusert oksidativt stress ble studert i primære nevroner og astrocytter 
fra stor- og lillehjernen, samt cellelinjer. Cellekulturene ble behandlet med N-acetyl cystein (NAC) som 
øker cellulært GSH eller med dietylmaleat (DEM) som reduserer cellulært GSH-innhold. Fluorescens-
mikroskopi ble benyttet til identifisering og kvantifisering av cellulær ROS og GSH i levende celler. 
Reduksjon av GSH førte til økt cellulært opptak av MeHg og forsterket MeHg-indusert oksidativ stress. 
Redusert GSH-nivå i nevroner i forhold til astrocytter viser betydningen av nevron-glia interaksjon med 
hensyn til MeHg nevrotoksisitet. Økningen av MeHg i cerebellare nevroner kan forklare økt følsomhet 
av cerebellare nevroner i forhold til cerebellare astrocytter. Modulasjonen av GSH forklarer i noen grad 
forskjellen i ROS-endringer i cerebellare og kortikale kulturer. Behandling med NAC eller DEM førte 
til økt cellulært opptak av MeHg i cerebellare kulturer i forhold til kortikale kulturer.  
Epidemiologiske studier av fiskespisende populasjoner har gitt noe forskjellig resultat med hensyn til 
hvordan MeHg kan påvirke hjernens utvikling. Mengden av ernæringsfaktorer som dokosaheksaensyre 
(DHA) kan påvirke MeHg-giftighet og bidra til å forklare uoverensstemmelsene i de ulike studiene. I 
denne avhandlingen har vi sett på hvordan DHA kan påvirke MeHg-indusert nevrotoksisitet i cellelinjer 
og primær-cellekulturer. I primær cellekulturer ble det vist hvordan DHA kan redusere mengden av 
MeHg i cellene samt redusere den oksidative effekt. Dette støtter hypotesen om at næringsstoffer fra 
fisk kan bidra til å beskytte hjernen mot MeHg.  
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Hg   mercury  
MeHg   methylmercury 
PCB’s   poly chlorinated biphenyls 
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CNS  central nervous system 
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DCF   dichlorofluorescein 
FID  flame ionization detector 
MTT  [3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide] 
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4III. Summary 
Methyl mercury (MeHg), a metal known and used for various purposes over many 
years became recognized as a neurotoxicant during the 1950’s. In spite of decades of 
research, the toxic mechanisms of MeHg still remain an enigma. It can react rapidly 
with any thiol group and since this binding is reversible, it can jump freely from one 
protein thiol group to another. Therefore, it can damage any protein present in the 
cellular machinery. There is no single specific mechanism of action ascribed to MeHg 
and its toxicity likely involves multiple coordinated effects on several parallel processes 
in the cell.  
One of the major mechanisms behind MeHg-induced toxicity is via generation of 
reactive oxygen species (ROS) and depletion of glutathione (GSH). The balance 
between the oxidative and reductive cellular processes is critical for MeHg-induced 
neurotoxicity. Tissue culture systems being less complex than the heterogenous brain 
were selected as a model for studying the changes in these cellular processes after 
MeHg exposure. Moreover, cell cultures can provide new insights into the mechanisms 
of neurotoxic compounds. The role of MeHg-induced oxidative stress was studied in 
primary neurons and astrocytes from cerebrum and cerebellum and in neuronal and 
glial cell lines. The cell cultures were treated with N-acetyl cysteine (NAC) which is 
known to increase the cellular GSH or with Di-ethyl maleate (DEM) which decreases 
the cellular GSH status. The technique of fluorescence microscopy allowed the 
identification as well as quantification of cellular ROS and GSH in live cells. The 
relationship between GSH and MeHg concentrations was also estimated. The depletion 
of GSH increased the MeHg accumulation and enhanced MeHg-induced oxidative 
stress. Conversely, supplementation with GSH precursor protected against MeHg 
exposure in vitro. The presence of increased GSH in neurons as compared to astrocytes 
indicated the importance of neuronal-glial interactions with respect to MeHg 
neurotoxicity. In addition, the increased cell-associated MeHg in cerebellar neurons 
provided an explanation for the increased susceptibility of cerebellar neurons as 
compared to cerebellar astrocytes. To a certain extent, the modulation of GSH also 
explained the differential sensitivity of MeHg towards ROS generation in cerebellar 
and cortical cultures. The increased cell-associated MeHg was observed in cerebellar 
cultures after treatment with NAC or DEM as compared to cortical cultures. Since in 
vitro cultures could be influenced by changes in cell density and concentration of 
5neurotoxic compounds; the importance of using an optimum concentration, time and 
cell density in cell cultures for assessing MeHg toxicity was also addressed.
There have been discrepancies in the outcomes of epidemiological studies estimating 
the effect of MeHg from fish diet. The availability of nutritional factors such as 
docosahexaenoic acid (DHA) might influence MeHg toxicity and may explain the 
discrepancies from the different studies. Therefore, the effect of DHA on modulating 
MeHg-induced neurotoxicity was studied in cell lines as well as primary cell cultures. 
In the cell lines, DHA augmented the response of MeHg-induced oxidative effects. 
However, in primary cell cultures the importance of DHA to reduce the cell-associated 
MeHg and prooxidant response from MeHg was addressed. This novel finding 
supported the hypothesis that fish-derived nutrients can offer possible neuroprotection 
from MeHg as well as highlighted the importance of using an appropriate model for 
investigating DHA and MeHg-induced effects. 
6IV. List of papers
1. Kaur, P., Schulz, K., Heggland, I., Aschner, M., and Syversen, T.  
 The use of fluorescence for detecting MeHg-induced ROS in cell cultures.
 Toxicology in Vitro 2008; Accepted for publication and in press. 
2. Kaur, P., Aschner, M., and Syversen, T.
Glutathione modulation influences methyl mercury induced neurotoxicity in primary 
cell cultures of neurons and astrocytes.
Neurotoxicology 2006; 27: 492-500. 
3. Kaur, P., Aschner, M., and Syversen, T.
 Role of glutathione in determining the differential sensitivity between the cortical and 
cerebellar regions towards mercury-induced oxidative stress.
 Toxicology 2007; 230: 164-177. 
4. Kaur, P., Schulz, K., Aschner, M., and Syversen, T.
Role of docosahexaenoic acid in modulating methylmercury induced neurotoxicity. 
Toxicological Sciences 2007; 100: 423-432. 
5.  Kaur, P., Heggland, I., Aschner, M., and Syversen, T.  
Docosahexaenoic acid may act as a neuroprotector for methylmercury-
induced neurotoxicity in primary neural cell cultures.
(Submitted to Neurotoxicology) 
7V.  List of all my publications
1. Kaur, P., Yousuf, S., Ansari, M.A., Almas Siddiqui, A., Ahmad, A.S., and Islam, F. 
Tellurium-induced dose dependent impairment on antioxidant status: differential 
effects in cerebrum, cerebellum and brain stem of mice. Biological Trace Element 
Research 2003, 94: 247-258. 
2. Kaur, P., Yousuf, S., Ansari, M.A., Ahmad, A.S., and Islam, F. Dose and duration 
dependent alterations by tellurium on lipid levels: differential effects in cerebrum, 
cerebellum and brain stem of mice. Biological Trace Element Research 2003, 94: 259-
271.
3. Kaur, P., and Islam, F. Nutritional Aspects of mustard oil. Book Chapter in Health, 
Nutrition and Value Addition of Indian Mustard. Eds. D. Mathur and N. Bharti, 2003, 
62-70.
4. Islam, F., Zia, S., Sayeed, I., Kaur, P., and Ahmad, A.S. Effect of selenium on lipids, 
lipid peroxidation, and sulfhydryl group in neuroendocrine centers of rats. Biological 
Trace Element Research 2004, 97: 71-82. 
5. Kaur, P., Schulz, K., Heggland, I., Aschner, M., and Syversen, T. The use of 
fluorescence for detecting MeHg-induced ROS in cell cultures. Toxicology in Vitro 
2008; in press. 
6. Kaur, P., Aschner, M., and Syversen, T. Glutathione modulation influences methyl 
mercury induced neurotoxicity in primary cell cultures of neurons and astrocytes. 
Neurotoxicology 2006; 27: 492-500. 
7. Kaur, P., Aschner, M., and Syversen, T. Role of glutathione in determining the 
differential sensitivity between the cortical and cerebellar regions towards mercury-
induced oxidative stress. Toxicology 2007; 230: 164-177. 
8. Kaur, P., Schulz, K., Aschner, M., and Syversen, T. Role of docosahexaenoic acid in 
modulating methylmercury induced neurotoxicity. Toxicological Sciences 2007; 100: 
423-432.
9. Kaur, P., Heggland, I., Aschner, M., and Syversen, T. Docosahexaenoic acid may act 
as a neuroprotector for methylmercury-induced neurotoxicity in primary neural cell 
cultures. (Submitted to Neurotoxicology). 
10. Kaur, P., Evje, L., Aschner, M., and Syversen, T. The in vitro effects of 
selenomethionine on methylmercury-induced neurotoxicity. (In preparation). 
8VI. Introduction
a) Background 
Mercury (Hg) is a metal of many uses that has been known for thousands of years. Hg 
occupies the atomic number 80 in the periodic table and has an atomic weight of 200.6. 
The physical properties of Hg include a density of 13.6 and its melting and boiling 
points at normal pressure are -38.9 and 356.6oC, respectively. Thus, it is the only metal 
which is liquid at room temperature. Hg exists in nature mainly as three different 
molecular species; elemental (Hgo), inorganic (e.g., Hg+, Hg2+) and organic (e.g., 
methylmercury, ethylmercury, phenylmercuric acetate). One of the organic forms of 
Hg: methylmercury (MeHg) became a prime environmental heath issue during the 
1950’s.
The first case of fatal occupational poising caused by MeHg was recorded in 1863 
where the researchers working on the synthesis of organic mercurials were gravely 
affected (Edwards, 1865, 1866). Later in 1940, the first report on MeHg neurotoxicity 
by occupational exposure in four adults was reported (Hunter et al., 1940). Several 
catastrophic epidemics resulting from environmental contamination at the two cities in 
Japan - Minamata from 1953-1956 (Igata, 1993) and Niigata from 1964-1965 (Tsubaki 
et al., 1967) highlighted the potentially disastrous effects of MeHg. In mid-1960’s in 
Sweden (Westöö, 1966) MeHg was recognized as a widespread environmental issue. 
Later in the late 1960’s and early 1970’s exposure to MeHg via consumption of bread 
baked with Hg treated seed grains in Iraq (Bakir et al., 1973) caused a large outbreak of 
human intoxication from organic Hg. Similar incidents in Pakistan, Guatemala and 
Ghana led to the recognition of MeHg as a ubiquitous environmental toxicant 
(Clarkson, 2002). It is a hazardous trace metal that is still released into the environment 
from both natural and anthropogenic sources (ATSDR, 1999; US EPA, 1997). Hg 
released from such sources is sustained in the marine ecosphere (Stokes and Wren, 
1987; Veiga et al., 1994) and becomes methylated to MeHg in the upper sedimentary 
layers of sea or lake beds by the action of microorganisms (Jensen and Jernelöv, 1969). 
The MeHg formed is rapidly taken up by the living organisms in the aquatic 
environment. MeHg is then biomagnified through the food chain from 10,000-100,000 
times (US EPA, 1997; Wiener et al., 2003). After bioaccumulation it reaches humans 
through fish consumption (Clarkson, 1997; Kamps et al., 1972; Spry and Wiener, 
1991). A recent study by Boudou et al., (2005) reported higher concentrations of Hg in 
9a gold mining river at French Guiana resulting in high MeHg content in the fish. In 
general, nearly all fish contain detectable amounts of MeHg which when consumed in 
large amounts by humans can exert neurotoxic effects due to MeHg overload (Clarkson 
et al., 1988). However, the enrichment of MeHg in the food chain is not uniform. It is 
dependent upon the Hg content in the water and bottom sediments, pH of the water, 
redox potential of the water, species, age and size of the fish. In addition Boudou et al.,
(2005) also reported that environmental conditions such as anoxia favor the growth of 
microorganisms which increase the methylation of Hg and might account for high 
concentrations in fish. They observed that fish collected in rivers downstream of gold 
mining sites in French Guiana had 8-fold higher concentrations of MeHg than fish 
collected upstream.  
The current recommended maximal dose for MeHg is 0.4ȝg/kg body weight/day by the 
World Health Organization and US Food and Drug Administartion and more recently 
0.1µg/kg/day by the US Environmental Protection Agency (US EPA, 1997, 2001). 
Unfortunately, these levels can easily be attained with only a few meals of fish per 
week, depending on the source of the fish and its position in the food chain. The Hg 
intake via fish consumption in different epidemiological studies is shown in Table 1. In 
populations which consume large amounts of  fish as for example on the Faroe Islands, 
an increase in hair-Hg levels up to 4.27 ppm during pregnancy were associated with 
impaired psychomotor test performance of the child at 7 years of age (Grandjean et al.,
1997). This population consumed mainly pilot whale which contained both MeHg and 
PCB’s (poly chlorinated biphenyls). This type of diet led to average cord blood MeHg 
level of 22.9 µg/l and was correlated with deficits in neurophysiological and 
neuropsychological tests (eg finger tapping speed, reaction time on a continued 
performance task, cued naming, deficits in motor, attention and verbal tests) performed 
in children. In a follow up study performed on 14 year-old children at Faroe Islands it 
was reported that correlation between MeHg exposure via fish and deficits in scores of 
neurological tests were still persistent (Debes et al., 2006). Moreover, Budtz-Jorgensen 
et al., (1999), reported that PCB’s were not responsible for these effects. In Japan, 
strong association between the prevalence of mental retardation and Hg concentration 
in the umbilical cord were reported at Minamata (Harada, 1978) and Niigata (Tsubaki 
and Irukayma, 1977). In another study from New Zealand (Kjellstrom and Kennedy, 
1985) intake of MeHg via fish increased the maternal hair Hg levels to 5-20 ppm. In 
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this study, maternal hair Hg levels exceeding 6 ppm correlated with the deficit in the 
Denver developmental screening test and neurological screening test in children at 4 
years of age. However, studies carried out on the Seychelles (Davidson et al., 1998; 
Huang et al., 2005; Myers et al., 2003) showed no adverse effects at maternal hair Hg 
level of 6.8 ppm. Another epidemiological study in the province of Quebec, Canada 
(Keown-Eyssen et al., 1983) also indicated no consistent relation between hair MeHg 
levels of 24 ppm or lower in the mother during pregnancy and developmental outcomes 
in the female offspring. Although, the objective of both the Faroe Island and Seychelles 
studies was to evaluate the offspring of mothers exposed to MeHg during pregnancy, 
the apparent differences in outcomes between the Faroe Islands and Seychelles studies 
could be due to many reasons. For example, the effect of some of the confounding 
factors, such as socioenvironmental factors, differences in genetic disposition, 
nutritional status as well as pattern of exposure can be difficult to control and adjust for 
in the statistical analysis. In addition in the Faroe Islands study, umbilical cord blood 
was the preferred biomarker of exposure, although maternal hair was also collected and 
analyzed. In addition in the Seychelles study, maternal hair was used as the measure of 
fetal exposure. Moreover, the assessment of neurodevelopmental outcomes depends 
greatly upon the appropriate uses of the test for the skills being assessed and the age of 
the subjects being evaluated. At the Faroe Islands the tests were performed on 7 year 
olds but on the Seychelles it was performed on 5½ year (66 months) olds. Furthermore, 
the first testing in the Seychelles study was performed on 6-month-olds (Myers et al.,
1995) using the Denver Developmental Screening Test. This test is specific but 
insensitive, especially when administered to 6-month-olds. The co-exposure with 
confounders such as selenium, and omega-3 fatty acids might also influence the 
outcome of these studies. Conversely, it is also possible that the different populations 
simply produced different results due to differences in genetic dispositions. 
The MeHg content in food products excluding fish varies from few µg to 50µg/kg 
(Bouquiaux, 1974). Consumption of MeHg-contaminated bread in Iraq led to MeHg 
concentrations in hair exceeding 50 ppm and was correlated with severe psychomotor 
retardation (Marsh et al., 1980). In the United States in 1970, a case of MeHg exposure 
was reported in a family that consumed the meat of a pig fed treated grain (Likosky et 
al., 1970). Even recent contamination of rice with MeHg has also been reported from 
Jiangsu province in China (Shi et al., 2005). Therefore, the risk of exposure to MeHg 
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via contaminated food still persists and requires constant surveillance. When 
neurological impairments from MeHg consumption appear, the duration of exposure is 
of importance for recovery and rehabilitation. From the epidemiological studies, the 
duration of exposure can be divided into three categories (Table 1): a) chronic exposure 
at high levels as in Minamata or b) acute exposure at high levels as in Iraq or c) chronic 
exposure at low levels such as in Sweden, the Faroe Islands and the Seychelles. The 
outlook for recovery and rehabilitation seems to be better in the case of acute exposure 
compared with prolonged exposure (Amin-Zaki et al., 1978). However, exposure levels 
seem to be a critical factor in determining the extent of recovery.  
Table 1. Compilation of some epidemiological studies of MeHg exposure 
Epidemiological study Hg intake Source 
Prolonged low level
Swedish Population 
(Swedish Expert Group, 1971) 
1-20 µg/day Fish 
American Samoan Population 
(Marsh et al., 1974) 
200-300 µg/day Fish 
Seychelles
(Davidson et al., 1998) 
12 fish meals/week leading to 
maternal hair level of 6.8 ppm 
(median) 
Fish
Faroes
(Grandjean et al., 1997) 
1-3 fish meals/week leading to 
maternal hair level of 4.27 ppm 
(geometric mean) 
Fish and pilot 
whale
New Zealand 
(Kjellstrom and Kennedy, 1985) 
fish consumption leading to 
maternal hair level of 5-20 ppm 
Fish
High level exposure
Minamata and Niigata 
(Eto, 1997) 
5 mg/day Fish
Iraq
(Bakir et al., 1973) 
hair levels above 50 ppm 
blood levels above 500 µg Hg/l 
Wheat
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b) Pharmacokinetics 
MeHg can be absorbed via skin (Friberg et al., 1961) or after inhalation where it readily 
penetrates the membranes of the lung at absorption level of 80% of the exposure. MeHg 
ingested via food is likely to be bound to proteins in the intestinal tract (Aberg et al.,
1969). The hazards involved in the intake of MeHg via food or occupational exposure 
is due to efficient absorption (90%) and long retention time (half life of 70 days) in 
man. After ingestion, the distribution to the blood compartment is complete within 30 
hrs and the blood levels account for about 7% of the ingested dose (Kershaw et al.,
1980). In blood, MeHg is accumulated to a larger extent in the red cells bound to 
cysteinyl residues on the beta-chain of the hemoglobin molecule (Doi, 1991). From the 
blood MeHg is distributed slowly to the organism and the equilibrium between blood 
and body is not reached until 4 days (Kershaw et al., 1980). It was shown by using 
radiolabeled MeHg that equilibrium between blood and brain requires about 3 days 
(Aberg et al., 1969). In humans about 10% of body content of MeHg is retained in the 
brain. MeHg is incorporated into the hair during its formation. The MeHg concentration 
in blood and hair reflects the body burden. The ratio of blood/hair concentration in man 
is 1/250 under steady state conditions (Skerfving, 1974). 
Demethylation of MeHg into inorganic Hg is the key step in the excretion process of 
MeHg. This process occurs mainly through microbial activity within the intestine 
(Rowland et al., 1984) or in vitro in rat liver microsomes (Suda and Hirayama, 1992) 
and has also been reported to occur in brain but at a slower rate (Charleston et al.,
1995). MeHg is predominantely excreted (about 90%) via the fecal route. The net 
excretion rate in humans is approximately 1% of the body content at non-symptomatic 
body burden (Swedish Expert Group, 1971). Most of the MeHg is eliminated through 
liver into the bile and through the kidney into the urine. From the bile most of the 
MeHg gets absorbed in the gut leading to enterohepatic circulation of MeHg. Slower 
excretion of MeHg via urine has been reported to result in more toxicity in female rats 
as compared to male rats (Hirayama and Yasutake, 1986). MeHg is also excreted in the 
breast milk which is about 5% of the MeHg in the maternal blood (Bakir et al., 1973). 
An influence of diet on the excretion rate of MeHg has also been shown (Landry et al.,
1979) since the diet interferes with the reabsorption of MeHg in the lower part of the 
intestines.  
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MeHg has a remarkable affinity for the anionic form of sulfhydryl (-SH) groups (log K, 
where K the affinity constant is in the order of 15-23) (Hughes, 1957). Despite the high 
thermodynamic stability of the MeHg-SH bond, very rapid exchange of MeHg between 
-SH groups is known to occur (Rabenstein and Fairhurst, 1975). In cells, MeHg can 
form a complex with the -SH containing amino acid cysteine (Bridges and Zalups, 
2004). The MeHg-S-Cys complex behaves as a mimic of the neutral amino acid, 
methionine, which is a substrate of the neutral amino acid transporter system L 
(Landner, 1971). This mimicry has been reported to be responsible for MeHg uptake 
into the cells. For MeHg, the uptake into the cells is both an active, energy dependent 
(e.g. MeHg-cysteine) as well as passive uptake (e.g. MeHgCl) depending on the Hg 
species (Aschner et al., 1990) 
c) Neurological disturbances
The brain and the central nervous system (CNS) are the primary target sites where the 
adverse effects of MeHg are observed (ATSDR, 2003; WHO, 2000). MeHg is a potent 
neurotoxicant that affects both the developing and mature CNS (Atchison, 2005; 
Clarkson et al., 1988). There is usually a latent period of weeks to months between 
exposure and the onset of symptoms (Clarkson et al., 2003). The pathological changes 
found in adult brain are different when compared to fetal brain (Lapham et al., 1995). 
The pathology of the Minamata disease is shown in Fig. 1 where MeHg poisoning 
results in focal damage in adults as compared to the widespread and diffuse damage in 
the fetal brain. MeHg from mother’s blood is transported through the placenta to the 
fetus (Reynolds and Pitkin, 1975). The brain levels of MeHg in fetus can be higher than 
in the mother (Berlin and Ullberg, 1963). In infants, MeHg poisoning results in an 
unspecific infantile cerebral palsy (Swedish Export Group, 1971) involving ataxic 
motor disturbances and mental symptoms. The brain is found to be hypoplastic upon 
autopsy with a symmetrical atrophy of cerebrum and cerebellum. The histological 
features involve decreased number of neurons and distortion of cytoarchitecture in the 
cortical areas (Choi et al., 1978; Takeuchi, 1977). In less severe cases, psychomotor 
retardation and increased incidence of seizures has been reported (Marsh et al., 1980). 
These generalized symptoms in infants with neuronal loss throughout the brain are 
mainly irreversible. A body burden of 0.5 mg/kg body weight in pregnant women may 
result in inhibited brain development of the fetus with psychomotor retardation of the 
child.
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In adults, chronic MeHg poisoning results in degeneration of the sensory cerebral 
cortex and severe neurological disturbances, such as paresthesia in the distal 
extremities, ataxia, sensory and speech impairment, and constriction of the visual field 
(Bakir et al., 1973; Elhassani, 1982; Harada, 1995). In severe cases clonic seizures have 
been observed. The pathological changes involve general neuronal degeneration with 
gliosis in the calcarine, precentral and postcentral areas of the cerebral cortex. In the 
cerebellar cortex, loss of granular cells in the neocerebellum is observed (Hunter and 
Russell, 1954). The signs and symptoms associated with the changes in the specific 
regions of the adult brain can be reversible at a very slow rate. Specific therapies 
against MeHg poisoning are aimed at lowering the MeHg body content and thus the 
concentration at the site of action. In severe cases the first choice is hemodialysis 
combined with extracorporeal infusion of chelating agents such as N-acetylcysteine 
(NAC) or cysteine and oral administration of DMPS- 2,3-dimercapto-1-propane 
sulfonate (Aposhian, 1998).  
Adult Non-fetal infantile Congenital 
Fig.1. Pathology of Minamata disease: Comparison of the distribution of lesions 
among the adult, non-fetal infantile and congenital Minamata disease 
(Takeuchi, 1968). 
d) Biochemical mechanisms behind MeHg toxicity  
Hg is covalently bound to the carbon moiety in MeHg (CH3-Hg+). The carbon-Hg bond 
is chemically stable because of the low affinity of Hg for oxygen. MeHg exists only at a 
very low concentration as a free, unbound cation in biological systems (Hughes, 1957) 
and the chloride form is highly soluble in organic solvents and lipids. MeHg is found to 
bind to protein -SH groups of amino acids such as cysteine which is also present in 
glutathione (Clarkson, 1993). This affinity of Hg for sulphur and sulfhydryl groups is a 
major factor underlying the biochemical properties of MeHg. The binding of MeHg to -
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SH groups of proteins in membranes and enzymes may interfere with the membrane 
structure and function. This in turn, results in interference with the enzyme activity of 
several cellular targets. The main mechanisms involved in MeHg toxicity include: 
x inhibition of macromolecule synthesis (DNA, RNA and protein),  
x microtubule disruption,  
x increase in intracellular Ca2+ with disturbances of neurotransmitter function,  
x oxidative stress, 
x excitotoxicity, secondary to altered glutamate homeostasis.  
MeHg reacts with DNA and RNA resulting in changes in secondary structure of these 
molecules (Gruenwedel and Lu, 1970). This could give rise to disturbances in the 
synthesis of protein, DNA and RNA and has been reported by several authors using 
cells (Choi et al., 1980; Gruenwedel and Cruikshank, 1979), mice (Chang et al., 1972) 
and rats (Farris and Smith, 1975) as a model. Inhibition of protein synthesis (Verity et
al., 1975), as well as increased protein synthesis due to reactive astrogliosis has been 
reported after in vivo exposure to MeHg (Brubaker et al., 1973). Using neuron enriched 
fractions from rat brain it has been shown that in vivo exposure to MeHg may induce 
temporary changes in protein and RNA synthesis (Syversen, 1977, 1982), indicating 
that some types of neurons may be able to repair the initial reduction in protein 
syntheis. It is still open for speculation as to whether such repair-mechanisms may play 
a role in the cellular selectivity of MeHg’s action in the nervous system. Due to the 
ability of MeHg to react with DNA and RNA, it has been proved to be mutagenic 
(Ramel, 1972). It can also cause chromosomal aberrations in human lymphocytes 
(Skerfving et al., 1974) and leukocytes and in bone-marrow cells from MeHg exposed 
cat (Miller et al., 1979).
Inhibition of polymerization of tubulin by MeHg (Fig. 2.) is among major mechanisms 
behind MeHg toxicity (Sager et al., 1982). Microtubular fragmentation has been 
reported in cultured primary rat cerebellar granular neurons at a MeHg concentration of 
0.5-1µM (Castoldi et al., 2000). Since microtubules participate in cell division, their 
fragmentation by MeHg results in antimitotic effects. Fragmentation of microtubule by 
MeHg results in inhibition of neuronal migration and causes degeneration of neuritis 
(Choi et al., 1980).
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   Healthy neuron 
Intact microtubules
  MeHg exposure 
Microtubules break down 
Neurons clump together 
Cease functioning 
Fig. 2. Methylmercury targets the cell structure and disturbs neuron migration 
(Mercury and the developing brain, Report of the National Environmental Trust 
for Clean the Air). 
MeHg depolarizes the presynaptic membrane which increases the Na2+ and decreases 
K+ ion concentration. This causes disruption of Ca2+ homeostasis leading to increased 
intracellular Ca2+ concentration (Komulainen and Bondy, 1987; Oyama et al., 1994). 
Blockers of voltage dependent Ca2+ channels prevent the appearance of neurological 
signs (Sakamoto et al., 1996). The damaged cell membranes due to increased Ca2+
levels are associated with disruption of neurotransmitter signaling. Disturbances in 
neurotransmitter concentrations (Fig. 3.), such as increased release of dopamine, 
glutamate, GABA-gamma amino butyric acid, glycine, choline (Bondy et al., 1979) and 
acetylcholine (Juang, 1976) also occur after MeHg exposure. Inhibition of uptake of 
excitatory amino acids like glutamate and aspartate by astrocytes has been one of the 
major mechanisms behind MeHg-induced neurotoxicity (Aschner et al., 1993, 2000). 
Antagonists of the N-methyl-D-aspartic acid receptor have been reported to inhibit the 
toxic effects of MeHg (Park et al., 1996).
MeHg also alters the cellular energy metabolism. It affects respiratory control in 
synaptosomes both in vitro and in vivo (Fox et al., 1975; Verity et al., 1975). It causes 
decrease in state 3 and increase in state 4 respirations. Effects on mitochondrial 
respiration in the brain have been reported to occur at 10-100µM MeHg (Verity et al.,
1975; Von Burg et al., 1979). This causes inhibition of glycolysis and tri-carboxylic-
acid cycle activity and decrease in adenosine triphosphate utilization. Since nervous 
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tissue is strictly dependent on glucose, high oxygen utilization and excitability renders 
it especially susceptible.  
Fig. 3. Methylmercury blocks the release of neurotransmitters such as 
dopamine (Mercury and the Developing Brain, Report of the National 
Environmental Trust for Clean the Air). 
Alterations in the heme biosynthetic pathway and porphyrinurias have also been 
reported after MeHg exposure (Woods and Fowler, 1977; Woods et al., 1991). These 
porphyrins have been reported to catalyze the formation of reactive oxygen species 
(ROS) (Woods and Sommer, 1991). Since the adult human brain consumes >20% of 
the oxygen utilized by the body and comprises only 2% of the body weight, the ROS 
are generated at high rates during oxidative metabolism of the brain (Clarke and 
Sokoloff, 1999). Disruption of redox cellular homeostasis by an excess of ROS 
formation leading to cumulative oxidative stress appears to be an important contributor 
to MeHg neurotoxicity (Fig. 4. and 5.). MeHg is known to induce oxidative stress 
(Sarafian, 1999) both in vitro and in vivo which is evidenced by membrane 
peroxidation (Ali et al., 1992; Fujimoto et al., 1985; LeBel et al., 1990; Sarafian and 
Verity, 1990; Shanker and Aschner, 2003; Taylor et al., 1973; Yee and Choi, 1994; 
Yonaha et al., 1983). The production of ROS by MeHg exacerbates the toxicity by 
facilitating cell death through apoptotic pathways. Inhibition of glutathione peroxidase 
(GPx) by MeHg further potentiates lipid peroxidation. Conversely, several studies have 
demonstrated partial amelioration of MeHg toxicity in the presence of antioxidants by 
inhibition of ROS (Gasso et al., 2001; Sanfeliu et al., 2001; Shanker and Aschner, 
2003). A major source of MeHg-increased ROS generation may be the mitochondrial 
electron transport chain. The damaged mitochondrion increases oxidative stress, 
leading to decrease in defense mechanisms such as reduced glutathione (GSH) content 
and excitotoxic damage. Both these triggered chains of events interact leading to 
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amplification of toxicity. In addition, inhibition of protein synthesis and microtubule 
assembly adds to the serious consequences on neurotransmission and neural cell 
development. Interaction of MeHg with respiratory enzyme complexes and its ability to 
cause oxidative damage in the mitochondria has been reported by Verity et al., (1975) 
and Yee and Choi, (1996). It has also been reported that MeHg causes increased ROS 
generation after stimulation of the ubiquinol: cytochrome c oxidoreductase complex in 
isolated mitochondria (Yee and Choi, 1996). Furthermore, blockage of the 
mitochondrial transition pore by cyclosporin A in brain synaptosomes has been 
reported to lower MeHg-induced ROS production (Myhre and Fonnum, 2001). MeHg 
binds to GSH which is one of the principal endogenous antioxidants and this binding is 
reported to be responsible for the excretion of MeHg. Decreased GSH levels usually 
parallel increased oxidative stress by MeHg (Sarafian and Verity, 1990; Sarafian et al.,
1994; Vijayalakshmi and Sood, 1994). The upregulation (Li et al., 1996) or the 
induction of an increased synthesis of GSH (Choi et al., 1996) has been reported to be 
neuroprotective against MeHg-induced neurotoxicity. 
Oxidative stress and antioxdant defences Mechanisms of oxidative stress
Fig. 4. Methylmercury causes increase in oxidants and decrease in antioxidants 
(James, 2005). 
Other effects of MeHg include inhibition of spermatogenesis (Homma-Takeda et al.,
2001), immune responses (Koller, 1980), changes in the axonal flow in the sciatic nerve 
(Wakabayashi et al., 1976) and decreased activity of lysosomal enzymes (Vinay and 
Sood, 1991).
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e) Advantages and disadvantages of brain cells and cell cultures: implications for 
neurotoxicity
Brain tissue is a heterogeneous system comprising of two distinct compartments known 
as neurons and glia (Van den Berg et al., 1969). The neuron is the functional unit 
responsible for transmitting and processing information in the nervous system 
(Augustine, 2004). The glial cells play a significant role by supplying neurons with a 
number of metabolites and precursors. In the cerebrum, the neurons are greatly 
outnumbered by glial cells (Nedergaard et al., 2003). In contrast to cerebrum, the 
cerebellum is one of the most evolutionary primitive brain regions where neurons 
outnumber the glial cells (Andersen et al., 1992). Of three main types of glial cells-
microglia, oligodendrocytes and astrocytes, the astrocytes regulate the chemical 
environment of the brain. Due to the heterogeneity and complexity of the brain, the 
molecular mechanisms leading to neurological abnormalities following exposure to 
neurotoxic substances are difficult to study in the CNS in vivo. In a heterogeneous 
system numerous factors such as neural, hormonal, and hemodynamic are not under 
experimental control. Hence, a simplified model, such as tissue culture, is indispensable 
as a tool for studying the cellular and molecular mechanisms of neurotoxicity produced 
by a variety of compounds. Tissue cultures allow direct evaluation of the effects of 
toxic agents on the CNS as toxins can be easily added and withdrawn from the cultures, 
and long term effects may be studied. In addition, tissue culture systems also could be 
very useful in studying the modification of the effects of neurotoxic substances since 
they can provide clues to reduce the effectiveness of neurotoxic agents and new insights 
into the mechanisms of their action.  
Primary cultures are prepared by taking cells directly from an organism in contrast to 
cell lines which originate from transformed cells (e.g. tumor cells). The primary cells 
are obtained after an initial mechanical and/or enzymatic dissociation of the tissue and 
consist of normal diploid cells. Once the cellular purity, content and degree of 
maturation have been established, monolayer cultures of astrocytes and neurons afford 
a host of advantages over in vivo techniques. Cell morphology, protein synthesis and 
release (myelin), energy metabolism, receptor interaction, neurotransmitter uptake and 
release, electrophysiological studies utilizing patch clamping as well as electrolyte and 
non-electrolye uptake and release can be easily studied using cell cultures. Direct 
effects of chemicals on a relatively homogeneous population allows for study of 
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specific aspects of the growth and differentiation of cells, as well as the kinetics of 
uptake and metabolism of the parent compound. The culture model also makes it 
possible to study regional specialization, and can be extended to study astrocytic-
neuronal interactions by co-culturing astroglial and neuronal cells as two separate 
monolayers in the same culture dish (at a distance from each other). The system may 
provide information on how astrocytes respond to the neuronal environment, and vice 
versa, and how astrocytic homeostasis affects neuronal development and function.  
Primary cell cultures are advantageous over the cell lines as their properties and 
metabolism closely resemble that of corresponding cells in vivo. On the other hand, cell 
lines are economical, easy to grow and handle and possess several features of nerve and 
glial cells. For example dibutyryl cAMP agents produce morphological differentiation 
in both glioma and normal embryonic glial cells (Vernadakis and Nidess, 1976).
Although the use of cultured astrocytes and oligodendrocytes in toxicity testing has 
emerged as a powerful tool to evaluate the responses of target cells at the cellular and 
molecular level, one must bear in mind some intrinsic pitfalls of culture systems.  
For example for the use of primary cells, the timing is very crucial to obtain viable 
cells. In mice, the neurogenesis is almost completed at the time of birth. Only the 
interneurons in cerebellar cortex such as granule neurons develop from day 2 until 15 
after birth. Therefore, the tissue must be at a particular developmental stage which 
favors the cultivation of a particular cell type. Such developmental stage requirements 
might be a challenge if cellular maturity or age is an important aspect of the toxicity 
mechanism. In addition, the cells can undergo varying degrees of differentiation. From 
the toxicologic viewpoint, the extent of cellular differentiation must be carefully 
defined, since multiple phenotypic states may exhibit different toxicologic 
responsiveness and the phenotypic expression of cells in culture may itself be the target 
of toxic insult. Since glial cells and neurons promote mutual functional differentiation 
of each other, cell types resulting from purified cultures may result in undifferentiated 
cells or cells with altered differentiation, making results difficult to interpret. The 
sensitivity of undifferentiated cells to neurotoxicants has not been assessed.   
The effect of MeHg in cell cultures depends on the total biomass present. It was shown 
by Furukawa et al., (1982) that cytolethal sensitivity of the mitotic cells to MeHg was 
equal to that of exponentially growing cells. Gülden et al., (2001), reported that for a 
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variety of toxic compounds including MeHg, the EC50 values increased with increasing 
cell concentration. They concluded that cell binding can significantly affect the 
availability of compounds in vitro and thus their toxic potencies and toxic equivalency 
factors. In addition, it was also reported that the presence of albumin concentrations in 
medium greatly influences the toxic potency of MeHg (Seibert et al., 2002). This may 
be due to the presence of extra binding sites for MeHg, which can dilute the effective 
concentration. Therefore, caution should be taken when extrapolating results from in
vitro experiments to the whole brain. Moreover, diverse cell types exhibit different 
sensitivity towards MeHg, which might be dissimilar from the in vivo situation. These 
differences in sensitivity can also be seen within different species. For example, the 
monkey brain resembles the human brain with respect to effects of MeHg exposure as 
the calcarine cortex is highly vulnerable and changes in vision are detected early 
(Berlin et al., 1975b). However, in rats, peripheral neuropathy is most commonly 
observed (Cavanagh, 1973). The characteristic effect of MeHg, i.e. loss of granular 
cells preceding Purkinje cell loss is found in rats (Klein, 1972), mice (MacDonald and 
Harbison, 1977) and rabbit cerebellum (Jacobs et al., 1977). However in rats, the 
haemoglobin has an extra chain, so there is a greater retention of MeHg in blood which 
to some extent limits the utility of rat as a model. Therefore, use of appropriate model is 
crucial for studying MeHg toxicity.
In addition, it still needs to be determined whether the receptor phenotype observed in
vitro accurately reflects the in vivo situation. The observed phenotype might be a 
function of culture conditions or inherent astrocyte heterogeneity. While chemicals can 
be easily added and withdrawn from the cultures, and their effects directly probed in 
culture systems, caution should be used when correlating effects occurring in vitro to 
those which are observed in the intact animal, where additive interactions are likely to 
occur. One must remember several concepts:  
x A number of different, sometimes competing, processes influence the ability 
of a toxin to attack and destroy specific cells. Metabolism of the administered 
agent by a non-target cell or tissue may be responsible for bioactivation and/or 
detoxification of the compound or its metabolite, affecting the vulnerability of 
the cells to the neurotoxin.
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x A cell culture is many fold more homogeneous and simpler than any tissues, in 
particular the CNS. Removal of many cell types and barriers can facilitate 
diffusion or even active transport of the compound or its metabolite, limiting 
or enhancing toxicity by determining at which sites the toxin can reach 
sufficiently high concentrations to interfere with vital cellular processes.  
x The capacity of the cell to repair or replace damaged organelles or enzymes 
can also be critical in determining cell survival after toxic insult and may 
obviously depend on neighboring cells and physical barriers, which may be 
absent in the culture altogether. Accordingly, characteristics which are 
described as advantageous in particular circumstances may be described as 
disadvantageous in others. 
f) Neuronal- glial interactions with respect to MeHg neurotoxicity 
Neuronal-glial interactions play an important role in MeHg neurotoxicity (Fig. 5.). 
Neuronal damage in response to MeHg exposure has been suggested to be mediated by 
astrocytes (Aschner et al., 2007; Morken et al., 2005). Astrocytes support neurons and 
supply them with various factors which neurons themselves are unable to synthesize. 
The tripeptide glutathione (Ȗ-glutamyl-L-cysteinylglycine) is the most abundant thiol 
present in mammalian cells. It is also involved in the disposal of exogenous peroxides 
by astrocytes and neurons. MeHg toxicity has been reported to be caused by the 
reduction in the amount of intracellular GSH (Choi et al., 1996; Miura and Clarkson, 
1993; Sarafian et al., 1994) which leads to augmentation of ROS formation (Ali et al.,
1992; Gasso et al., 2001; Sanfeliu et al., 2001; Sarafian, 1999; Shanker and Aschner, 
2003; Sorg et al., 1998; Yee and Choi, 1996). Astrocytes contain higher concentrations 
of GSH than neurons (Kranich et al., 1996; Sagara et al., 1993). The astrocytes supply 
the rate limiting precursor molecules, e.g. cysteine, glycine and glutamine to neurons 
for GSH synthesis (Shanker and Aschner, 2001). Other enzymes which are present only 
in astrocytes include pyruvate carboxylase (Shank et al., 1985) and glutamine 
synthetase (Norenberg and Martinez-Hernandez, 1979). Glutamine synthetase is the 
enzyme required for synthesis of glutamine which is one of the substrates for 
glutathione synthesis. Glutamine is first converted to glutamate (Sonnewald et al.,
1993) by the mitochondrial enzyme phosphate activated glutaminase (Kvamme et al.,
1988). Glutamate then binds to cysteine and is converted to Ȗ-glutamylcysteine with the 
help of the enzyme Ȗ-glutamylcysteine synthetase. The Ȗ-glutamylcysteine is then acted 
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upon by glutathione synthetase which leads to the formation of glutathione. Glutamine 
is also an important precursor for amino acids such as glutamate and GABA 
(Schousboe et al., 1977; Sonnewald et al., 1993). During glutamatergic 
neurotransmission, glutamate is released from neurons and is mainly taken up by 
astrocytes (Danbolt, 2001) and this is compensated for by the net flow of glutamine 
from astrocytes to neurons. The reason for such compensation is that the major 
anaplerotic enzyme in brain, pyruvate carboxylase, is only present in astrocytes, as 
pointed out above. The spontaneous release of glutamate and GABA from neurons 
(Atchison and Hare, 1994) and the inhibition of its uptake in astrocytes (Aschner et al., 
2000) are among the major mechanisms of MeHg-induced neurotoxicity. The drain of 
GABA from neurons to astrocytes is relatively modest (Hertz and Schousboe, 1987) 
and the glutamine transport is more intense in glutamatergic neurons than cortical 
neurons and astrocytes (Su et al., 1997). However, in the glutamatergic cerebellar 
granule cells, glutamate re-uptake might be important for glutamate homeostasis 
(Olstad et al., 2007). 
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Fig. 5. Neuronal-glial interactions with respect to MeHg neurotoxicity (Modified 
from Shanker et al., 2005a)
 Long chain poly unsaturated fatty acids (PUFA’s) such as docosahexaenoic acid 
(DHA; 22:6n-3) are essential for normal brain development (Innis, 1991). Astrocytes 
can readily release DHA into the extracellular fluid while neuronal DHA is not readily 
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released (Garcia and Kim, 1997; Kim et al., 1999; Moore, 2001). Neurons cannot 
produce DHA because they lack desaturase activity (Moore et al., 1991). The transport 
of DHA from astrocytes to neurons is considered trophic. Astrocytes may protect 
neurons from low doses of MeHg by upregulation of metallothionein synthesis 
(Aschner et al., 1997). Upon MeHg exposure, astrocytes also increase local interleukin-
6 release that leads to neuroprotection in 3 D brain cell cultures (Eskes et al., 2002).
Therefore, the interactions between neurons and glial cells play a critical role in MeHg-
induced neurotoxicity.
g) Prevailing conundrums behind MeHg neurotoxicity
Conundrum 1: The relationship between GSH and MeHg concentration in brain is 
unknown. Molecular oxygen is essential for many biological events associated with 
aerobic metabolism which results in the constant formation of ROS (Powis et al., 
1995). Conversely, GSH is the most abundant thiol tripeptide present in mammalian 
cells for scavenging ROS (Fang et al., 2002; Roberts et al., 1980). Several reports have 
implicated a critical role of GSH in modulating MeHg neurotoxicity (Choi et al., 1996;
Miura and Clarkson, 1993). However, it still remains unclear whether the protection 
afforded by GSH is due to protection against ROS generated by MeHg or due to the 
reduction of the intracellular concentration of MeHg. In addition, little is known 
concerning the relationship between GSH and MeHg concentrations in specific 
anatomical regions of the brain. 
Conundrum 2: The reason for the selective sensitivity of certain brain regions to MeHg 
remains unknown. MeHg has a high association constant (15<pKa<23) for -SH groups 
(Carty and Malone, 1979). It can react with any -SH group (Hughes, 1957) leading to 
conformational changes and thus inhibition of many enzymes. This indicates that more 
than one mechanism may contribute to the expression of MeHg-induced neurotoxicity. 
However, the existence of similar enzymes such as acetylcholine esterase in different 
regions makes it difficult to reconcile this with the specific pattern of neurological 
damage associated with MeHg, such as in the cerebellar granule cell layer and in the 
calcarine region of the occipital cortex in humans (Choi et al., 1978; Eto, 1997; Hunter 
and Russell, 1954; Takeuchi, 1982) and in rodent brains (Nagashima, 1997). Moreover 
in the cerebellum, which is a major target of MeHg effects, the Purkinje cell layer 
which tends to accumulate more Hg is spared as compared to the sensitive granule cell 
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layer (Clarkson and Strain, 2003). Neuronal dysfunction has been proposed to be 
secondary to disturbances in astrocytes (Allen et al., 2001). However, the sparing of 
Purkinje cells and the sensitivity of granule cells in the cerebellum cannot be attributed 
solely to the vulnerability of cerebellar astrocytes towards MeHg, for under these 
circumstances, both Purkinje and granule cells would be expected to respond in a 
similar fashion. Therefore, despite considerable scientific efforts, the reason for this 
selective degeneration of certain areas of the nervous system has not been satisfactorily 
explained.
Conundrum 3: The effect of DHA on modulation of MeHg-induced neurotoxicity 
remains unknown. The major dietary route of human exposure to MeHg is via the 
ingestion of seafood for adults (Clarkson, 1997; Kamps et al., 1972; Spry and Wiener, 
1991). The nervous system is also highly enriched in long chain PUFA’s which are also 
provided via consumption of fish and mother’s milk (Franco et al., 2006; Manfroi et
al., 2004). DHA, in particular, is the most abundant PUFA in the brain which is 
essential for normal brain function (Kim, 2007; Salem et al., 1999; Uauy et al., 2001).
DHA plays a crucial role in diverse cellular functions ranging from controlling the cell 
body size (Ahmad et al., 2002) and outgrowth of neurites by promoting cell 
differentiation (Ikemoto et al., 1997) to being antiapoptotic (Akbar and Kim, 2002) and 
neuroprotective (Martin, 1998). The availability of DHA is dependent upon type and 
amount of fish consumed and it varies within different epidemiological studies. On the 
Seychelles (Davidson et al., 1998), fish consumption was reported to be around 12 fish 
meals/week. On the Faroe Islands (Grandjean et al., 1997) the diet included whale meat 
and 1-3 fish meals/week. At Minamata and Niigata (Eto, 1997), tuna consumption was 
around 5mg/day. The discrepancies in the outcomes of the studies on the Seychelles 
(Davidson et al., 1998; Myers et al., 1997) and the Faroe Islands (Grandjean et al., 
1997) have raised the question of whether risks outweigh the benefits arising from the 
combined exposure to a neurotoxicant and neuroprotectant. Therefore, there is a need to 
investigate whether DHA supplementation would modulate the susceptibility of neural 
cells to MeHg exposure. Knowledge of this could assist in assessing the risk/benefit 
from their exposure. 
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VII. Aims  
The aim of the study was to explore the cellular and molecular mechanisms behind MeHg 
toxicity. More specifically, we wanted to elucidate the role of MeHg-induced oxidative 
stress by introduction of agents which are known to influence MeHg neurotoxicity.
1. Evaluate the concentration, time and cell density dependent effects of MeHg on 
generation of ROS using C6-glial and B35-neuronal cell lines. (Paper 1)
2. To investigate the role of GSH modulation on MeHg-induced neurotoxicity using 
primary cell cultures of cerebellar neurons and astrocytes. (Paper 2) 
3. To determine whether GSH is responsible for the differential sensitivity between the 
cortical and cerebellar cultures towards MeHg-induced oxidative stress using primary 
cell cultures. (Paper 3) 
4. To investigate the effect of DHA in modulating MeHg-induced neurotoxicity in C6-
glial and B35-neuronal cell lines. (Paper 4) 
5. To investigate the effect of DHA in modulating MeHg-induced neurotoxicity in 
primary astrocytes and neurons from the cerebellum. (Paper 5) 
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VIII. Materials and methods 
a) Primary cell cultures and cell lines  
Cerebellar granule cells are predominately glutamatergic, whereas cortical neurons 
are mainly GABAergic (Hertz and Schousboe, 1987; Yu et al., 1984). Glutamatergic 
neurons were prepared from the cerebella of 7-day-old mice according to the method 
described by Schousboe et al., (1989). GABAergic neurons were prepared from the 
cerebra of the pups obtained from pregnant mothers at 15 days of gestation 
(Schousboe et al., 1989). Addition of cytosine arabinoside to the culture medium 
between 24 to 48 hrs after preparation of neurons reduced the glial cell concentration 
to 5% (Messer, 1977). The cytosine arabinoside acts by being cytotoxic to the 
dividing glial cells whereas neurons which are in the post-mitotic stage are spared 
(Hertz et al., 1989. The neuronal cultures were used one week post isolation.
Cerebellar Neurons Cerebellar astrocytes 
Fig. 6. Primary cell cultures from the cerebellum prepared from 7-day-old 
mice. Phase contrast images taken with Nikon Eclipse TE 2000-S microscope 
equipped with SPOT RT Digital Camera. 
Primary astrocytes express a large variety of ion channels, neurotransmitter receptors 
and are glial fibrillary acidic protein (GFAP) specific (Verkhratsky and Steinhauser, 
2000). Cerebellar and cortical astrocytes were prepared from the respective brain part 
according to the method of (Hertz et al., 1989). For the cerebellar astrocytes, 7-day-
old mice were used whereas for cortical astrocytes, pups were used within 24 hrs of 
birth. The method used for the preparation of cerebellar astrocytes has been estimated 
to yield about 95% astrocytes (Hertz et al., 1989). Minor contaminations in these 
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cultures are phagocytic cells and oligodendrocytic precursors. The regular medium 
changes and use of dibutyryl-cAMP reduces the contamination from phagocytic cells. 
The insignificant amount of oligodendrocytes is due to their formation between three 
weeks to three months. Astrocytes were used for the experiment 21 days post 
isolation. Poly-D-lysine coating was used for all the cell cultures to improve the 
attachment of cells. Cell lines are widely used as a model to study neurotoxicity since 
they are economical, easy to grow and possess several features of nerve and glial 
cells. Therefore, both C6-glial (Benda et al., 1968) and B35-neuronal (Schubert et al.,
1974) cell lines from rat brain were selected to represent each cell type in the present 
study.
Cell type
x In Paper 1 and 4, C6-glial and B35-neuronal cell lines have been used.
x In paper 2, 3 and 5, primary neurons and astrocytes from cerebellum were 
used. In addition, cortical neurons and astrocytes were used in paper 2 where 
dialyzed serum was used for culturing cortical neurons to reduce the 
glutamate content in the media.  
Cell density
x In Paper 1 and 4: For C6 cell line, 60,000 cells per well and for B35 cell line, 
160,000 cells per well were seeded in 24 well plates. 
x For Paper 2: Kainic acid was used for culturing cerebellar neurons and the 
cells were seeded at a density of 0.5 cerebella / 24 well culture plate 
(astrocytes) and 0.8 x 106 cells / ml (neurons).  
x For Paper 3 and 5: Kainic acid was not used for culturing cerebellar neurons 
since it did not significantly inhibit the GABA content in neurons (Sonnewald 
et al., 2004, 2006). The cells were seeded at a density of 1 cerebella / 24 well 
culture plate (astrocytes) and 1.5 x 106 cells / ml (neurons).  
b) Fluorescence microscopy 
Fluorescence reflects the property of some atoms, molecules or solids to absorb 
energy and get excited to a high energy level and then subsequently emit light of 
longer wavelength while coming back to the lower energy level. The intensity of 
fluorescence is very weak in comparison with the excitation light. Fluorochromes are 
stains that attach themselves to visible or sub-visible molecules and have highly 
specific biological targets. The technique of fluorescence microscopy has become an 
29
essential tool in biology and the biomedical sciences. The application of an array of 
fluorochromes has made it possible to identify cells and sub-microscopic cellular 
components with a high degree of specificity amid non-fluorescing material. Through 
the use of multiple fluorescent labels, several target molecules can be identified 
simultaneously. In many cases it allows work on live cells where it is important to 
prevent background staining and photobleaching in order to improve the resolution. 
In a fluorescent microscope, light from the arc lamps or lasers passes thorough field 
and aperture diaphragms and then into a cube which contains a set of interference 
filters, dichoric mirror, barrier filter and excitation filter. After passing through the 
objective and being focused onto the specimen, the specimen gets excited. The 
reflected fluorescence is then filtered by the emission filter which is then sent to the 
eyepieces or detector. The oxidative effects of MeHg were detected with the help of 
fluorescent probes CMH2DCFDA- chloro methyl derivative of di-chloro di-hydro 
fluoresceindiacetate and MCB- monochlorobimane. The fluorescent probes 
CMH2DCFDA (485/535) and MCB (360/465) can be used for detecting the ROS and 
GSH content in live cells. The oxidation of the CMH2DCFDA dye by ROS yields a 
fluorescent product, 2ƍ, 7ƍ-dichlorofluorescein (DCF), which is retained inside the cell 
(Shanker et al., 2004; Shimazawa et al., 2005; Liu et al., 2001). It has been reported 
that CM-H2DCFDA dye is more useful than other DCF dyes since the addition of a 
chloromethyl group gives a better retention and more reliable fluorescent signals in 
live cells as compared to other DCF dyes (Liu et al., 2001). The content of reduced 
GSH can be determined by MCB (Bellomo et al., 1997) as it can diffuses passively 
across the plasma membrane into the cytoplasm where it binds with the reduced form 
of GSH leading to formation of blue fluorescent adducts (Haugland, 1996). The 
Fluorescent images of the cell cultures were taken with Nikon Eclipse TE 2000-S 
microscope which was equipped with SPOT RT Digital Camera. The excitation 
filters B-2A and UV-2 E/C*(DAPI) were used at the microscope and the emitted 
fluorescence was detected at Victor3TM 1420 Multilabel counter by scanning the 
whole well using the desired excitation and emission wavelengths.  
c) Gas chromatography-flame ionization detection 
Chromatography is a technique for separating chemical substances that relies on 
differences in partitioning behavior between a flowing mobile phase and a stationary 
phase to separate the components in a mixture. The sample is carried by a moving gas 
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stream through a tube packed either with a finely divided solid material or which may 
be coated with a film of a liquid. The substances having the greater interaction with the 
stationary phase are retarded to a greater extent and consequently separate from those 
with smaller interaction. As the components elute from the column they can be 
quantified by a detector and/or collected for further analysis. The flame ionization 
detector (FID) uses an air-hydrogen flame to break the components to produce ions. 
The ions are collected on a biased electrode and produce an electrical signal. The 
greater the concentrations of the component, the more ions are produced and greater is 
the current. Because of its simplicity, sensitivity, and effectiveness in separating 
components of mixtures, gas chromatography is one of the most important tools in 
chemistry. It is widely used for quantitative and qualitative analysis of mixtures and for 
the purification of compounds. Since in paper 4 and 5, the cells were supplemented 
with the fatty acid DHA, it was important to detect the amount and type of intracellular 
fatty acids after DHA exposure.   
d) Other methods 
Cytotoxicity: Determined by changes in mitochondrial dehydrogenase activity using 
colorimetric 2.4 mM MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium 
bromide] reduction assay (Carmichael et al., 1987; Dahlin et al., 1999).
Cell-associated MeHg: 99% pure 14C-labeled MeHg (20 mCi/mmol) obtained from 
American Radiolabeled Chemical (St.Louis, Mo, USA) was used and the 
radioactivity was counted in a 1450 Micro Beta Trilux Liquid scintillation counter 
(Wallac, Perkin Elmer Life Sciences, Norway).  
Estimation of protein: Total cellular protein was used as a measurement of biomass 
and all the measurements were corrected with respect to the biomass present. Protein 
concentration was determined by the method of Lowry et al., (1951) using Folin 
reagent with bovine serum albumin as a standard.  
IX. Data analysis 
All results are given as mean ± standard deviation. Differences between groups were 
analyzed statistically with one-way ANOVA followed by the least significant 
difference or Tukey post hoc test for multiple comparisons and p<0.05 was 
considered statistically significant. In addition, a two or three-way ANOVA was 
carried out to evaluate the interactive effects between different parameters. 
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X. Summary of papers 
a) Paper 1 
For evaluating the concentration-, time- and cell density- dependent effects of MeHg, three 
different MeHg concentrations (5, 10 and 25µM) and time periods (30, 50 and 90 min) and 
two different cell densities (day3 v/s day4) were selected. For this purpose, C6-glial and 
B35-neuronal cell lines were selected. The MeHg-induced ROS was measured by the 
fluorescent probe, CMH2DCFDA. The cell-associated MeHg was measured with 14C-
labelled MeHg. For C6 cells, a significant increase (p<0.05) in MeHg-induced ROS was 
observed at 10 and 25µM MeHg for both 30 and 50 min time intervals. For B35 cells, a 
significant increase in ROS was observed only at 25µM MeHg. The amount of ROS 
produced with 25µM MeHg varied significantly (p<0.001) at different time periods. For 
both the cell lines, significant cell density-dependent differences (p<0.05) were observed 
at 10µM MeHg treatment for 50 minutes. A concentration-dependent increase in cell 
associated-MeHg provided an explanation for increased ROS at 30 and 50min. However, 
the cell density dependent differences in ROS were not due to differences in cell 
associated-MeHg. Therefore it was concluded that special attention should be focused 
upon concentration, exposure time and cell density for assessing MeHg-induced ROS 
effects by fluorescence. 
b) Paper 2 
In order to evaluate the effect of GSH on MeHg-induced cytotoxicity, the 
intracellular GSH content was modified by pretreatment with NAC or di-ethyl 
maleate (DEM) for 12 hrs. For this purpose, primary cell cultures of cerebellar 
neurons and astrocytes were used. ROS and GSH were measured using the 
fluorescent indicators CMH2DCFDA and MCB. Cell-associated MeHg was 
measured with 14C-radiolabeled MeHg. Mitochondrial dehydrogenase activity was 
detected by MTT. The MTT timeline study was also performed to evaluate the 
effects of both the concentration and duration of MeHg exposure. Treatment with 
5µM MeHg for 30 min led to significant (p<0.05) increase in ROS and reduction 
(p<0.001) in GSH content. Depletion of intracellular GSH by DEM further increased 
the generation of MeHg-induced ROS in both cell cultures. Conversely, NAC 
supplementation increased intracellular GSH and provided protection against MeHg-
induced oxidative stress in both cell cultures. MTT studies also confirmed the 
efficacy of NAC supplementation in attenuating MeHg-induced cytotoxicity. The 
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cell-associated MeHg was significantly (p<0.02) increased after DEM treatment. In 
summary, depletion of GSH increased MeHg accumulation and enhanced MeHg-
induced oxidative stress, and conversely, supplementation with GSH precursor 
protected against MeHg exposure in vitro.
c) Paper 3 
The role of GSH behind the differential sensitivity between the cerebrum and 
cerebellum towards MeHg-induced toxicity was investigated. MeHg-induced oxidative 
insult was determined in primary neuronal and astroglial cell cultures of both cerebellar 
and cortical origins. The intracellular GSH content was modified by pretreatment with 
NAC or DEM. The ROS and GSH were measured with the fluorescent indicators, 
CMH2DCFDA and MCB. The cell associated-MeHg was measured with 14C-
radiolabeled MeHg. The cerebellar cell cultures were more vulnerable to ROS (p<0.02) 
than the cortical cell cultures after MeHg, NAC or DEM treatment. 
A trend towards significant interaction between origin×MeHg×pretreatment was 
observed only for the dependent variable, ROS (astrocytes p<0.06; neurons p<0.001). 
For GSH, a significant interaction between origin×MeHg was observed only in 
astrocytes (p<0.05). The increased content of GSH in cortical astrocytes as compared to 
cerebellar astrocytes accounted for the increased ROS production in cerebellar 
astrocytes. However, the similar content of GSH in cortical and cerebellar neurons after 
MeHg exposure did not provide an explanation for the increased susceptibility of 
cerebellar neurons. The cell associated-MeHg increased when cells were treated with 
DEM, and the cerebellar cultures were significantly different (p<0.05) from the cortical 
cultures. In summary, GSH modulation influenced MeHg-induced toxicity, and 
partially explained the differential sensitivity between the cortical and cerebellar 
cultures.  
d) Paper 4 
It is important to identify the biochemical mechanisms involved with fatty acids and 
MeHg exposure for understanding how fish consumption could modulate MeHg-induced 
neurotoxicity. For this purpose, the effect of DHA in modulating MeHg-induced 
neurotoxicity was investigated in C6-glial and B35-neuronal cell lines. Increased DHA 
content in both the cell lines after 24 hr supplementation was measured by gas 
chromatography. Decreased mitochondrial activity evaluated by MTT reduction indicated 
that 10µM MeHg treatment for 50 min led to a significant (p<0.001) and similar decrease 
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in MTT activity in both cell lines. However, DHA pretreatment led to more pronounced 
depletion (p<0.05) in the MTT activity in C6 cells as compared to B35 cells. Upon DHA 
and MeHg exposure, the C6 cells exhibited a more apparent decrease in GSH and increase 
in ROS (p<0.001) as compared to B35 cells. The cell associated-MeHg measurement 
using 14C-labelled MeHg indicated a decrease (p<0.05) in MeHg accumulation upon DHA 
exposure in both cell lines. These findings provide experimental evidence that although 
pretreatment with DHA reduced cell associated-MeHg, it caused increased ROS (p<0.001) 
and GSH depletion (p<0.05) in C6 cells. 
e) Paper 5 
The following reasons prompted us to ascertain the effects of DHA on MeHg-induced 
neurotoxicity in primary cell cultures. Firstly, the DHA exposure increased the MeHg-
induced ROS in tumor cell lines. We wanted to investigate whether primary cell 
cultures would respond similarly to DHA exposure. Secondly, the B35 neuronal cell 
line behaved differently from primary neuronal cells with respect to MeHg exposure. 
Therefore, the identification of these effects in primary cell cultures would help us in 
understanding the effect of potential natural modulators such as DHA in influencing the 
toxicity of fish-bound MeHg. This may improve the risk/benefit assessment of a MeHg-
containing fish diet. For this purpose, primary neuronal and astroglial cell cultures from 
cerebellum were selected. After individual or combined treatment with MeHg (10µM) 
and DHA (30 and 90µM), the neurons differed significantly (p<0.001) from astrocytes 
exhibiting increased ROS production and decreased MTT activity. After MeHg and 
30µM DHA treatment there were no changes in MTT or GSH content but significant 
decrease (p<0.001) in ROS was observed in both the cell types when compared to 
MeHg alone. The cell associated-MeHg measurements indicated reduced MeHg-
accumulation in both cell types (p<0.05) upon 30µM DHA exposure. Therefore it was 
established that DHA pretreatment effectively reduces cell-associated MeHg and 
prooxidant response from MeHg in both cerebellar astrocytes and neurons. This 
observation supported the hypothesis that fish-derived nutrients can possibly offer 
neuroprotection against MeHg-induced neurotoxicity.
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XI. Discussion 
Though considerable headway has been made in elucidating the effects of MeHg on the 
nervous system, it still remains an element of mystery. The underlying processes behind 
its mechanism of action are not very well understood. The reason for its selective 
sensitivity towards certain brain regions remains unknown. In addition, little is known 
concerning the cellular uptake of MeHg in various brain regions.
The considerable risk to the public from MeHg-contaminated food has raised the 
concern about the safe dose of ingested MeHg especially for pregnant women. Various 
regulatory agencies in the past have stressed uncertainities in their documentation 
regarding the effects of MeHg. The Joint FAO/WHO Expert Committee on Food 
Additives had reported in 1978 that ‘‘foetus may be more susceptible to MeHg toxicity 
than the adult’’ (JECFA, 1978). The workshop organized by Committee on 
Environmental and Natural Resources, Office of Science and Technology Policy and 
The White House in 1998 stated ‘‘These studies have provided valuable new 
information on the potential health effects of MeHg but significant uncertainties remain 
because of issues related to exposure, neurobehavioral endpoints, confounders and 
statistics, and design’’ (NIEHS, 1999). Later in 2000, the National Academy of 
Sciences committee reported that ‘‘60,000 children in the United States were at risk as 
a result of prenatal exposure’’ (National Research Council, 2000). However, they failed 
to provide any justification or explanation for that conclusion (Clarkson et al., 2003). 
Hence there is a possible discrepancy between the estimated effect of MeHg and its risk 
assessment. The issue which is a dilemma for the consumers and regulatory authorities 
is whether fish consumption should be encouraged for its nutritional benefits to the 
developing brain or should it be discouraged for the possible adverse effects of MeHg 
on the developing CNS? This suggests that there is a need to assess dietary nutrients as 
well as neurotoxic exposures in determining the risks and benefits of fish consumption 
(Myers et al., 2007). Therefore studies directed towards estimating the effect of 
modifiers such as essential nutrients available from seafood may provide a better 
assessment of risk from a contaimated fish diet. 
The work presented in this thesis attempts to explore the mechanism of action of MeHg. 
The cell culture models provide excellent tools to investigate the mechanistic 
pathyways since the effects on individual cell type could be determined. The present 
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work investigated the effects of MeHg on oxidative stress and identified the role played 
by GSH in modifying these effects. The differences in the MeHg-induced oxidative 
stress related effects in cerebellar and cortical cultures were reported. The cellular 
uptake of MeHg in these cell cultures was determined and correlated with the oxidative 
stress related effects. In addition, it identified the biochemical mechanisms behind DHA 
and MeHg exposure where DHA pretreatment effectively reduced cell-associated 
MeHg and decreased MeHg-induced ROS in primary cell cultures. 
It has been known that toxicity of MeHg is dependent upon the amount of biomass 
(Furukawa et al., 1982; Gülden et al., 2001; Seibert et al., 2002). Therefore, for all the 
experiments special attention was focused upon the use of consistent cell densities. In 
addition, for evaluating the effects of MeHg, three different concentrations and 
exposure intervals were selected to find out the optimum dose and time interval for the 
experiments. The dose of 5 or 10µM MeHg for 50min was selected for further 
experiments as consistent increase in ROS and cell associated-MeHg was observed for 
this exposure. The 10µM dose was used for estimating the toxicity in cell lines and 
5µM MeHg was used for primary cell cultures due to increased sensitivity of primary 
cell cultures as compared to cell lines. However, in paper 5, a dose of 10µM MeHg was 
used for primary cell cultures treated with DHA. This was attributable to introduction of 
small amounts of fatty acid free bovine serum albumin (FAF-BSA) along with DHA 
which diluted the effect of MeHg.
The well defined MeHg-induced effects on GSH depletion (Yee and Choi, 1996) and 
ROS generation (Ali et al., 1992; Gasso et al., 2001; Sanfeliu et al., 2001; Sarafian, 
1999; Shanker and Aschner, 2003; Shanker et al., 2004, 2005b; Sorg et al., 1998; Yee 
and Choi, 1996) were corroborated by primary cell cultures used in the presented 
papers. In papers 2 and 3, the effects of GSH modulation by NAC or DEM provided an 
important insight into the role of GSH in modulating the effect of MeHg-induced 
neurotoxicity in cerebellar and cortical cell cultures. Changes in intracellular MeHg 
content with GSH modulation provided an explanation for the increased susceptibility 
of neurons and cerebellar cultures towards MeHg-induced neurotoxicity as compared to 
astrocytes and cortical cultures. The papers 4 and 5 addressed the question of public 
health concern of whether PUFA intake from fish may modulate the MeHg-associated 
effects. It identified the biochemical mechanisms behind overall effects of fish 
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consumption (ie, providing DHA and MeHg). These papers may improve the basis for 
risk/benefit assessment of a MeHg-containing fish diet and our knowledge regarding the 
maximum permissible dose of MeHg from fish diet. 
a) MeHg-induced ROS effects  
In paper 1, it was observed that MeHg-induced ROS effects were dependent upon the 
MeHg concentration and exposure time. At 10µM MeHg in C6 cells, a consistent 
increase in ROS was observed with increased exposure time. In addition, at 30 and 
50min intervals there was an augmentation in ROS with increased MeHg concentration 
in both cell types. However, at 25µM MeHg there was a consistent decrease in ROS 
with an increase in exposure period. This decrease in ROS at 25µM MeHg could be due 
to leakage of dye from the cells. However, since the cell associated-MeHg did not 
decrease with time, the decreased ROS could be due to transition from the ROS 
generating state to the apoptic state in cells. Another possibility is the production of 
reducing agents in cells which could convert the dye to a reduced form. However, the 
reason for the decreased ROS needs to be determined. 
The ROS induction by MeHg was also observed to be dependent upon the cell density. 
At 10µM MeHg, decrease in fluorescence was associated with increase in cell density 
and increased cell-associated MeHg. The decreased fluorescence might be explained by 
the presence of extra binding sites for MeHg which may actually dilute the effective 
concentration of MeHg inside the cells. Another possibility could be the differences in 
cell cycle which may lead to changes in the intracellular microenvironment (Zurgil et 
al., 1996) which affects the ROS generation. 
b) Role of GSH in MeHg-induced neurotoxicity  
In Paper 2, it was determined that GSH played a major role in the cytotoxic effects of 
MeHg in cerebellar neurons and astrocytes. In the present study, NAC was effective 
in preventing ROS after MeHg exposure in both cell cultures. NAC, a relatively 
simple, nontoxic N-acetyl derivative of cysteine contains a thiol group that is 
stabilized by acetylation of the amino group (Aremu et al., 2008). NAC induces GSH 
synthesis (Zafarullah et al., 2003) and has been reported to enhance MeHg excretion 
in mice (Ballatori et al., 1998) and rats (Aremu et al., 2008). It has been reported that 
nucleophilic properties of NAC enables it to inactivate free radicals by direct 
conjugation and reduction (Moldeus et al., 1986). The loss of protective thiol groups 
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by DEM on the other hand further augmented MeHg-induced ROS. The low GSH 
content in neurons as compared to astrocytes was associated with increased 
intracellular MeHg and ROS in this cell type. The increased cell associated-MeHg in 
neurons as compared to astrocytes was different from what has been previously 
reported (Berlin et al., 1975a; Hargreaves et al., 1985). However, it provided an 
explanation for increased susceptibility of neurons as compared to astrocytes.  
GSH constitutes the most important antioxidant (Cooper, 1997) and the most 
abundant thiol with concentrations up to 10 mM in mammalian cells (Sies, 1979). 
Since MeHg is known to bind to GSH, the decrease in GSH is expected to decrease 
the cell-associated MeHg. However, the binding of MeHg to GSH is among one of 
the mechanisms for the efflux of MeHg. Therefore, the reported increase in cell-
associated MeHg after GSH depletion could be due to inhibition of MeHg efflux 
from the cells and has been previously observed to occur in endothelial cells (Kerper 
et al., 1996). Therefore, the limited availability of GSH might be one of the 
mechanisms responsible for the increased susceptibility of neurons to MeHg toxicity 
as compared to astrocytes.  
c) Role of GSH in the differential sensitivity of MeHg towards cerebellar and 
cortical cell cultures 
In Paper 3, the susceptibility of cells from the cerebrum and the cerebellum towards 
MeHg-induced toxicity were compared. It was reported that treatment with MeHg 
was associated with greater depletion of GSH in cerebellar astrocytes as compared to 
cortical astrocytes (Paper 3). This indicated that cortical astrocytes were more 
resistant to MeHg-induced depletion of GSH. However, the cortical astrocytes were 
more vulnerable when their GSH content was modified with NAC or DEM. This 
result might be attributed to the presence of a higher GSH content in cortical 
astrocytes possibly indicating that DEM is able to further deplete the available GSH 
content, whereas NAC is not able to upregulate the already elevated level of GSH in 
this cell type.  
The cortical neurons did not vary significantly from the cerebellar neurons with 
respect to their GSH content at either of the tested treatments. However, modulation 
of GSH content with NAC or DEM pretreatment did significantly influence the 
MeHg-induced GSH loss in neurons. This indicated that an increase in GSH content 
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with NAC pretreatment prevented MeHg-induced GSH loss in neurons, whereas a 
decrease in GSH content with DEM pretreatment augmented this loss. We further 
report that treatment with MeHg was associated with greater production of ROS in 
cerebellar cultures as compared to cortical cultures. The higher amount of GSH in 
cortical astrocytes after exposure to MeHg might explain the decreased production of 
ROS in this cell type. However, the similar content of GSH in cortical and cerebellar 
neurons after MeHg exposure does not provide an explanation for the increased 
susceptibility of cerebellar neurons. The increased susceptibility of cerebellar cultures 
could possibly be explained by the increase in cell associated-MeHg in these cultures 
as compared to cortical cultures. However, it has been postulated that the differential 
and selective vulnerability of cells is not simply due to the preferential accumulation 
of MeHg since Purkinje cells accumulate more Hg than granule cells (Leyshon-
Sørland et al., 1994). However, the study by Leyshon-Sørland using the silver nitrate 
technique detected only Hg2+, while the assessment of 14C labeled-MeHg provided a 
measurement of the presence of organic Hg only (Koh et al., 2002; Morken et al., 
2005; Simmons-Willis et al., 2002). Therefore, estimation of organic Hg in Purkinje 
and granule cells would provide a better assessment of organic Hg toxicity in these 
respective regions. 
In addition, the present study also points out the importance of using comparable cell 
densities for the study of MeHg toxicity as an increase in MTT activity was observed 
in MeHg treated cerebellar astrocytes when seeded from low to high concentrations. 
In addition, since GSH content only partially explained the differential MeHg-
sensitivity of cerebellar and cortical cultures, the role played by factors other than 
GSH in protecting cortical cultures from MeHg-induced ROS were discussed. Further 
studies on identifying these potentially selective targets are necessary.  
d) Role of DHA in moldulating MeHg-induced neurotoxicity 
There have been obvious differences in the dose effect relationships in population 
studies on the Faroe Islands (Grandjean et al., 1997; Harada, 1995; Keown-Eyssen et 
al., 1983; Kjellstrom et al., 1986, 1989) and other studies on the Seychelles 
(Davidson et al., 1998; Myers et al., 1997), Peru (Marsh et al., 1995) and in the US 
(Mozaffarian and Rimm, 2006; Oken et al., 2005). The availability of nutritional 
factors such as DHA might influence MeHg toxicity and may explain the 
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discrepancies from the different studies. Since dietary supplementation with DHA has 
been reported to enhance problem solving skills at 20 months of age (Willats et al.,
1998), boost the normal development of the visual system (Uauy-Dagach and 
Valenzuela, 1996) and result in better scores on visual and developmental tests 
(Makrides et al., 1994); there is a need to understand the overall effects of fish 
consumption (ie, providing DHA and MeHg). The identification of the biochemical 
mechanisms behind these effects may improve our basis to establish the maximum 
permissible dose of MeHg from fish diet. For that reason, the susceptibility of neural 
cells from MeHg and DHA exposure was investigated in paper 4 and 5. 
A relatively high concentration of MeHg (10µM) for a short time period (50min) was 
used in these studies which simulated the high level exposure conditions observed at 
Minamata (Eto, 1997). The MeHg content observed in these studies is 10-20 times 
that of the in vivo studies (Eto et al., 2001) or the same as in the extended in vitro 
exposure studies (Sakaue et al., 2006).
In paper 4, neural cell lines (C6-glial and B35-neuronal) were used. In the cell lines, 
the DHA exposure increased the relative DHA fraction of the total fatty acids content 
from 2-2.5% in control to 13-24% in DHA treated cells which is in agreement with 
the previous study (Leonardi et al., 2005). The 90µM DHA caused an increase in 
DHA, arachidonic acid (AA), eicosapentaenoic acid (EPA) and linoleic acid (LA). 
The LA can be desaturated and elongated to AA (Salem et al., 1999) and this is likely 
to occur in C6 and B35 cells. In the present study after DHA exposure, the C6-glial 
cells exhibited a higher content of DHA, AA and LA as compared to the neuronal-
B35 cells. This effect may be likely explained by the dependence of neurons on 
astrocytes for the availibilty of DHA (Moore, 2001).
The DHA exposure led to reduced cell associated-MeHg in both cell types which is in 
agreement with the previous study in rat brain (Berntssen et al., 2004) where a 
significant lower degree of MeHg was observed when rats were fed with naturally 
contaminated fish as compared to feed where MeHg was added chemically to the 
same matrix.  
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In cell lines, the combined exposure to MeHg and DHA resulted in a more 
pronounced reduction in MTT activity and GSH content and augmentation of ROS 
which was more evident in C6 cells. The B35 cells, on the other hand exhibited an 
increase in GSH content after MeHg exposure which might indicate an upregulation 
of protective mechanisms in this cell type. However, this is contrary to the 
characteristics of primary neurons which are not able to upregulate the synthesis of 
GSH on their own as they depend on astrocytes for this purpose (Wang and Cynader, 
2000). Our present observation of upregulated GSH in B35 cells may explain the 
previous finding by (Sakaue et al., 2005) of increased viability of B35 cells towards 
MeHg.
This peculiar behavior of B35 cells prompted us to study the effects of DHA and MeHg 
exposure in primary cells. This could provide a better understanding of the effects of 
DHA and MeHg treatment. Hence in paper 5, primary cerebellar cultures (astrocytes 
and neurons) were used. The amount of total lipid content in primary cells was not 
modified after exposure to DHA as compared with the cell lines. However, the amount 
of mg DHA/g test material in primary cells was reported to be similar to the levels 
previously reported in cell lines. This could be possibly due to the ability of cell lines to 
accumulate relatively high amounts of lipid droplets as compared to primary cells. In 
general, the cerebellar astrocytes had higher fatty acid content than neurons in all the 
tested groups possibly due to the dependence of neurons on the neighboring astrocytes 
for provision of long-chain PUFA’s (Moore et al., 1990; Spector and Moore, 1992). 
The primary neurons had higher Hg levels than B35-neuronal cell line in Paper 4 which 
may provide an explanation for the increased cytotoxicity in primary neurons to MeHg. 
Moreover, the reduced cell associated-MeHg observed in primary cells after DHA 
treatment may indicate its protective effect.
In primary cell cultures, the ability of DHA to afford protection against MeHg-induced 
generation of ROS was established. The combined exposure to DHA and MeHg was 
effective in attenuating the MeHg effect, reducing ROS levels in cerebellar astrocytes 
to levels indistinguishable from controls. Similar effects were seen in cerebellar 
neurons, where treatment with DHA significantly reduced ROS levels in comparison to 
MeHg treatment alone. These reduced ROS levels after DHA plus MeHg exposure in 
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cerebellar astrocytes and neurons did not induce any significant increase in MTT or 
GSH production when compared with MeHg alone. Moreover, significant reduction in 
MTT and GSH content was not associated with increased ROS production in neurons 
after 90µM DHA plus MeHg exposure. This effect could be possibly explained by the 
increased GPx activity by DHA which could lead to disposal of exogenous peroxides 
by conversion of reduced GSH to the oxidized form, GSSG. In primary cells, the DHA 
treatment was associated with an increase in EPA and decrease in AA possibly due to 
retroconversion (Alessandri et al., 2003). The decreased AA levels could also be 
integrated with an increase in GPx activity (Bryant et al., 1982; Vericel et al., 1992;
Weitzel and Wendel, 1993) and be related to protection against MeHg toxicity (Shanker 
et al., 2002). Therefore, the decrease in AA levels could be the mechanism behind 
decreased GSH and ROS levels. 
Differences between the cell lines and primary cells were observed with respect to the 
effect of DHA on MeHg toxicity. The cell lines used in paper 4 were derived from 
cancer tissue and the ability of DHA to augment ROS in these cancer cell lines might 
be attributed to the anti-tumor property of DHA (Calviello et al., 1998; Igarashi and 
Miyazawa, 2000; Merendino et al., 2005; Narayanan et al., 2003; Schley et al., 2005). 
Therefore the choice of cellular model for studying the effects of DHA is critical. The 
primary cells may be considered as an improved in vitro model which provided better 
insight into the mechanism behind the effect of DHA on MeHg toxicity. However, the 
primary cell cultures still represent a highly simplified model since these cultures are 
established using immature cells taken out of their anatomical context. Therefore, 
caution should be taken when extrapolating results from in vitro experiments to the 
whole brain. Nevertheless, the insight in mechanisms that can be provided from cell 
cultures may improve our experimental design for in vivo studies. As such, the 
recognition of the protective effects of DHA and identification of its mechanisms via in
vitro models may improve the basis for a risk/benefit assessment of a MeHg-containing 
fish diet.
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XII. Conclusion 
The present findings provide evidence that concentration, time and cell density play a 
crucial role while assessing MeHg-induced ROS effects (Paper 1). 
The confounding factors such as availability of GSH and fatty acids such as DHA 
effectively influenced MeHg-induced neurotoxicity. The modulation of GSH by NAC 
or DEM effectively played a major role in the cytotoxic effects of MeHg in primary cell 
cultures (Paper 2). To a certain extent, it also explained the differential sensitivity of 
MeHg towards cerebellar and cortical cultures (Paper 3).  
In the cell lines, DHA affected the peroxidative machinery and augmented the 
response of C6 and B35 cells to MeHg-induced oxidative effects (Paper 4). However, 
in primary cell cultures the novel ability of DHA to protect from the adverse effects 
of MeHg was highlighted. The reduction in cell-associated MeHg and the prooxidant 
response from MeHg challenge in primary cells with DHA was not associated with 
an increase in MTT activity or GSH content (Paper 5). This further highlights the 
importance of using an appropriate model for investigating DHA and MeHg-induced 
effects.
XIII. Future experiments 
The differential sensitivity of MeHg towards cerebellar and cortical cultures could be 
further explored. Since GSH content partially explained the differential sensitivity, the 
role of -SH groups after low and extended exposure to MeHg could be investigated. The 
capacity of these cultures to modulate GSH and ROS after low and extended MeHg 
exposure will be studied. In particular, the mechanism behind the differential sensitivity 
of granule and Purkinje cells will be explored. For this purpose, the authors would also 
like to expose the cell cultures to low level of MeHg throughout the maturation period. 
The protein and RNA isolated from these samples will then be tested for gene 
expression studies using microarrays and electrophoresis. These studies in different cell 
culture models would be later verified in animal studies. 
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Abstract
The eﬀect of methylmercury (MeHg) on reactive oxygen species (ROS) induction in neural cell lines was measured by the ﬂuorescent
probe, chloro methyl derivative of di-chloro di-hydro ﬂuoresceindiacetate (CMH2DCFDA). Three diﬀerent MeHg concentrations (5, 10
and 25 lM) and time periods (30, 50 and 90 min) were studied in C6-glial and B35-neuronal cell lines. In addition, the relationship
between MeHg-induced ROS and cell density (day3 vs. day4) was also explored. The 14C-labelled MeHg measurements were done to
determine the cell associated-MeHg content. At 30 and 50 min exposure, a signiﬁcant increase (p < 0.05) in MeHg-induced ROS was
observed at 10 and 25 lM MeHg for C6 cells and at 25 lM MeHg for B35 cells. However, the amount of ROS produced with
25 lMMeHg varied signiﬁcantly (p < 0.001) at diﬀerent time periods. For both the cell lines, signiﬁcant cell density dependent diﬀerences
(p < 0.05) were observed at 10 lM MeHg treatment for 50 min. MeHg treatments were associated with a concentration as well as cell-
density dependent increase in cell associated-MeHg. These ﬁndings provide experimental evidence that special attention should be
focused upon concentration, exposure time and cell density when assessing MeHg-induced ROS via ﬂuorescence.
 2008 Elsevier Ltd. All rights reserved.
Keywords: In vitro; Reactive oxygen species; Methylmercury; Fluorescence
1. Introduction
Methylmercury (MeHg) is a well known neurotoxicant
that aﬀects both the developing and mature central nervous
system (Clarkson, 2002; Aschner and Syversen, 2005).
Major human epidemics in Iraq (Bakir et al., 1973) and
Japan (Takeuchi, 1982) have established its neurotoxic
eﬀects. A major mechanism for MeHg-induced neurotox-
icity is through generation of reactive oxygen species
(ROS) (Saraﬁan and Verity, 1991; Ali et al., 1992; Yee
and Choi, 1996; Gasso et al., 2001; Shanker and Aschner,
2003). ROS, such as superoxide anion and hydroxyl radi-
cal, initiate oxidative cell damage and the brain is excep-
tionally sensitive to such free radicals. ROS can be
detected by the ﬂuorescent dye-CMH2DCFDA as its oxi-
dation yields a ﬂuorescent product, 20,70-dichloroﬂuoresce-
in (DCF), which is retained inside the cell (Shanker et al.,
2004; Kaur et al., 2006, 2007a). The CMH2DCFDA dye
has been extensively used for measuring cellular ROS
(Liu et al., 2001; Shanker et al., 2004; O’Donovan et al.,
2005; Shimazawa et al., 2005; Madhavan et al., 2006; Bai
et al., 2007). It has been reported that the addition of a
chloromethyl group to the CM-H2DCFDA dye gives a bet-
ter retention and more reliable ﬂuorescent signals in live
cells as compared to other DCF dyes (Liu et al., 2001).
0887-2333/$ - see front matter  2008 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tiv.2008.01.017
Abbreviations: CMH2DCFDA, chloro methyl derivative of di-chloro di-
hydro ﬂuoresceindiacetate; DMEM, Dulbecco’s minimum essential med-
ium; HEPES, N-2-hydroxy-ethylpiperazine N0-2-ethansulfonic acid; Me-
Hg, methylmercury; ROS, reactive oxygen species.
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Both C6 and B35 cells from rat brain which have been
extensively used as a glial (Benda et al., 1968; Schubert,
1974) and neuronal model (Schmid et al., 2000; Otey
et al., 2003; Diestel et al., 2005), respectively, were selected
to represent each cell type. The present study was designed
to assess the diﬀerences obtained with the DCF signal by
measuring the oxidative eﬀects of MeHg, assessing concen-
tration, time and cell density dependence. This comparative
approach allowed us to recognize the importance of these
factors for determining ROS-induced neurotoxicity by the
use of ﬂuorescence.
2. Materials and methods
2.1. Materials
24-well plastic tissue culture plates were purchased from
Falcon (Becton Dickinson Labware, USA). Fetal bovine
serum was purchased from PAA Laboratories, Pasching
(Austria). The medium for culturing C6 (F12 Kaighn’s
nutrient mixture) was purchased from Invitrogen (Nor-
way). The DMEM media used for culturing B35 cells was
purchased from PAA Laboratories, Pasching (Austria).
The ﬂuorescent indicator CMH2DCFDA was purchased
from Molecular Probes, Inc. (Eugene, OR, USA). Radiola-
beled 14C-MeHg was purchased from American Radiola-
beled Chemicals Inc. (St. Louis, MO, USA). MeHgCl
was purchased from K&K Laboratories (Plainview, NY,
USA). All other chemicals were of analytical grade.
2.2. Cell lines
The C6-glial and B35-neuronal cell lines were purchased
from the ATCC-LGC Promochem (Sweden). After three
passages, approximately 60,000 C6 and 160,000 B35 cells
per well per ml of media were seeded in 24 well plates
and incubated in a humidiﬁed 5% CO2/95% air atmosphere
at 37 C. The diﬀerent seeding concentrations were used as
the C6 cells divided at a much higher rate as compared to
B35 cells. To study the MeHg concentration and exposure
time dependent eﬀects, the cells were used at day 4 in vitro.
In addition, for investigating the cell density dependent
eﬀects, cells were used both at day 3 and day 4. The amount
of average protein for control C6 cells at day 3 and day 4 of
the experiment was 84.6 ± 7.6 and 135.8 ± 7.9 lg protein/
well. For control B35 cells, the amount of average protein
at day 3 and day 4 of the experiment was 87.2 ± 4.9 and
137.7 ± 7.5 lg protein/well. The seeding density was cho-
sen to facilitate the ﬂuorescence measurements.
2.3. Treatments
A stock solution of 1 mM MeHgCl was prepared in
5 mM Na2CO3. From this stock, a working solution was
prepared in HEPES buﬀer [122 mM NaCl, 3.3 mM KCl,
0.4 mM MgSO4  7H2O, 1.3 mM CaCl2, 1.2 mM KH2PO4,
10 mM glucose and 25 mM HEPES adjusted to pH 7.4
with 10 N NaOH]. On the day of the experiment, the cells
were washed once with HEPES buﬀer and incubated at
37 C with 450 ll of 0, 5, 10 or 25 lM MeHg per well for
30, 50 or 90 min interval.
2.4. Detection of intracellular ROS accumulation
Intracellular ROS accumulation was monitored in the
cells by adding CMH2DCFDA (7 lM) to the wells contain-
ing MeHg for the last 20 min of the 30, 50 and 90 min
exposure intervals. There were no washing steps involved
before the addition of CMH2DCFDA and were done only
after incubation with MeHg and CMH2DCFDA was com-
plete. The ﬁnal values were corrected for intracellular pro-
tein in each well and expressed as a percent of ﬂuorescence
in control wells as described previously (Kaur et al.,
2007b).
2.5. Cellular MeHg accumulation
The cell associated-MeHg studies were done with 14C-
labeled 10 lM MeHg (82 nCi/lg Hg) for 30, 50 and
90 min intervals. After incubation, the cells were washed
with ice cold buﬀer and treated with 1 N NaOH for
90 min. Samples were neutralized with 10 N HCl and
100 ll aliquots were added to 500 ll of Ultima Gold (Pack-
ard) scintillation cocktail. The samples were then counted
in a 1450 Micro Beta Trilux Liquid scintillation counter
(Wallac, Perkin Elmer Life Sciences, Norway) and radioac-
tivity was corrected for cellular protein in each well as
described previously by Kaur et al. (2007b).
2.6. Estimation of protein
Protein concentration was determined by the Folin
reagent with BSA as a standard (Lowry et al., 1951). The
protein was measured after MeHg and CMH2DCFDA
incubation using the same wells in which the ﬂuorescence
readings had been taken.
2.7. Data analysis
All results are given as mean ± standard deviation. Dif-
ferences between groups were analyzed statistically with
one-way ANOVA followed by the Tukey HSD post hoc
test for multiple comparisons and p < 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. MeHg-induced ROS eﬀects
ROS levels quantiﬁed by the ﬂuorescence intensity of the
oxidized product, DCF, for diﬀerent MeHg concentrations
and time of exposure are shown for C6-glial and B35-neu-
ronal cells in Figs. 1 and 2, respectively. A signiﬁcant
increase in ROS (p < 0.05) was observed with 10 lMMeHg
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in C6 cells for all the tested time intervals. However, at
25 lM MeHg, a signiﬁcant increase in ROS (p < 0.001)
was induced only at 30 and 50 min interval for both the cell
lines. In C6 cells, a signiﬁcant diﬀerence was observed
between 50 min and 90 min interval upon 10 lM MeHg
treatment. Likewise, at 25 lM MeHg, a signiﬁcant diﬀer-
ence was observed between the various time intervals for
both the cell lines. The protein values for each type of treat-
ment (provided below) did not vary signiﬁcantly with any
one the above treatments.
3.2. Cell associated-MeHg
Cell associated-MeHg measured with 14C-radiolabeled
MeHg for diﬀerent MeHg concentrations and time of
exposure are shown for C6-glial and B35-neuronal cells
in Figs. 3 and 4, respectively. A signiﬁcant increase in cell
associated-MeHg (p < 0.05) was observed with increasing
MeHg concentrations at all the tested time intervals for
both the cell lines. The cell associated-MeHg at 50 min
increased signiﬁcantly (p < 0.05) at 10 lM MeHg when
compared to 30 min in both C6 and B35 cells. In addition,
a signiﬁcant time dependent increase (p < 0.05) in cell asso-
ciated-MeHg was observed for B35 cells at 25 lM MeHg
dose.
3.3. Cell density dependent changes in MeHg-induced ROS
The MeHg-induced ROS level at 50 min interval for two
diﬀerent cell densities is shown in Fig. 5. In C6 cells, a
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Fig. 1. Cellular ROS detected by CMH2DCFDA ﬂuorescence in C6-glial cell line. Results are expressed as mean ± standard deviation (n = 6 replicates for
each cell type). The superscripts (a, b, c, d, and e) not showing common letters are signiﬁcantly diﬀerent (p < 0.05) from each other. Values were corrected
for protein content in each well (provided below) and determined as a percentage of ﬂuorescence with respect to control cells.
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Fig. 2. Cellular ROS detected by CMH2DCFDA ﬂuorescence in B35-neuronal cell line. Results are expressed as mean ± standard deviation (n = 6
replicates for each cell type). The superscripts (a, b, and c) not showing common letters are signiﬁcantly diﬀerent (p < 0.05) from each other. Values were
corrected for protein content in each well (provided below) and determined as a percentage of ﬂuorescence with respect to control cells.
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Fig. 3. Cell associated-MeHg in C6-glial cell line as measured by 14C radiolabeled MeHg. Results are expressed as ng Hg/mg protein, mean ± standard
deviation (n = 8 replicates for each cell type). The superscripts (a, b, c, and d) not showing common letters are signiﬁcantly diﬀerent (p < 0.05) from each
other. Values were corrected for protein content in each well.
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Fig. 4. Cell associated-MeHg in B35-neuronal cell line as measured by 14C radiolabeled MeHg. Results are expressed as ng Hg/mg protein,
mean ± standard deviation (n = 8 replicates for each cell type). The superscripts (a, b, c, d, and e) not showing common letters are signiﬁcantly diﬀerent
(p < 0.05) from each other. Values were corrected for protein content in each well.
Fig. 5. Cellular ROS detected by CMH2DCFDA ﬂuorescence in C6-glial and B35-neuronal cell line at day 3 and day 4. Results are expressed as
mean ± standard deviation (n = 6 replicates for each cell type). The superscripts (a, b, c, d, e, f and g) not showing common letters are signiﬁcantly
diﬀerent (p < 0.05) from each other. Values were corrected for protein content in each well and determined as a percentage of ﬂuorescence with respect to
control cells.
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signiﬁcant diﬀerence (p < 0.001) in ROS production was
observed for both 10 and 25 lM MeHg dose. In B35 cells,
cell density dependent diﬀerences in ROS production were
observed only for 10 lM MeHg dose.
3.4. Cell density dependent changes in cell associated-MeHg
Cell density-dependent changes in cell associated MeHg
(treated with 10 lM for 50 min) are shown in Table 1. For
both the cell lines, signiﬁcant diﬀerences in cell associated-
MeHg (p < 0.001) were observed between day 3 and day 4.
For both the cell lines, the cell associated-MeHg was more
at day 4 when compared to day 3. In addition, signiﬁcant
diﬀerences (p < 0.05) between the two cell types were
observed with C6 cells exhibiting more cell associated-
MeHg when compared to B35 cells.
4. Discussion
Oxidative stress occurs when the normal balance
between the oxidative events and antioxidant defenses is
disrupted either by loss of reducing agents/antioxidant
enzymes or by increased production of oxidizing species.
The present study is a part of a larger study aimed at mod-
ulation of MeHg toxicity and estimation of intracellular
ROS levels (Kaur et al., 2007b). Three diﬀerent MeHg con-
centrations used in the present study were selected on the
basis of MTT timeline study (Kaur et al., 2007b). The
exposure time was selected on the basis of previous uptake
studies showing maximum cell associated-MeHg level for
10 lM dose at 50 min of exposure (data not shown). The
MeHg content observed in the present study is 10–20 times
that of in vivo studies (Eto et al., 2001) and similar to cel-
lular levels after extended in vitro exposure studies (Sakaue
et al., 2006). For a range of toxic substances the eﬀective
dose during in vitro exposure must be considerable higher
than the in vivo situation when the target organ concentra-
tion is used as a dose indicator. In order to compare dose in
a range of cell lines and primary cultures we prefer to use
cell-associated mercury as the dose indicator rather than
the nominal concentration in culture media. This becomes
vital if the cell density varies between cell culture types or
the serum quantity/quality varies in the growth media.
The present study demonstrates increase in MeHg-
induced ROS in both C6 and B35 cells; corroborating ﬁnd-
ings from previous studies (Saraﬁan and Verity, 1991; Ali
et al., 1992; Yee and Choi, 1996; Shanker and Aschner,
2003; Shanker et al., 2004). In addition, it identiﬁes signif-
icant diﬀerences between diﬀerent MeHg concentrations
and time intervals for the production of ROS. From the
MTT Timeline study (Kaur et al., 2007b) it can be seen that
5 lM MeHg dose at 60 min interval resulted in a 15% and
4% reduction in MTT activity in C6 and B35 cell lines,
respectively. The primary cells on the other hand are more
sensitive (Kaur et al., 2006) exhibiting 40% and 50% reduc-
tion in MTT activity in cerebellar astrocytes and neurons.
This reduction in MTT activity was associated with signif-
icant induction of ROS in primary cells. However, the non-
signiﬁcant reduction in MTT activity observed at 5 lM
MeHg in cell lines (Kaur et al., 2007b), indicates that at this
dose the cells are not signiﬁcantly aﬀected to produce sig-
niﬁcant increase in ROS.
The decrease in the DCF signal at 25 lM MeHg dose
with increase in exposure time could have several explana-
tions including signal leakage, quenching and cellular defen-
sive response. Leakage of the DCF signal has been observed
in other cell types such as cancer cells (Ubezio and Civoli,
1994) and endothelial cells (Royall and Ischiropoulos,
1993). Quenching of the DCF ﬂuorescence signal may occur
as a result of lower intracellular pHwhich can be induced by
extracellular glutamate in primary neurons (Reynolds and
Hastings, 1995). Exposure to MeHg may result in increased
release of glutamate (Aschner et al., 2000) which in turn
may induce a lower intracellular pH. In the present study,
the cellular defensive response is shown by B35 cells which
counteract the ROS eﬀects more eﬀectively than C6 cells.
We have previously reported that this is most likely con-
nected to the ability of B35 cells to upregulate their GSH
content (Kaur et al., 2007b). We have made an attempt to
address all these considerations in our approach and thus
use relatively high MeHg concentration for short exposure
times with co-exposure to the DCF probe.
The present study demonstrates decrease in ROS with
an increase in cell density at 10 lM MeHg in both the cell
lines. The in vitro results can be inﬂuenced by the density of
cells in culture (Preobrazhensky et al., 2001). Moreover, the
eﬀect of MeHg depends on the total biomass present
(Furukawa et al., 1982). It was reported by Gulden et al.,
2001 that for a variety of toxic compounds including
MeHg, the EC50 values increased with increasing cell con-
centration. They concluded that cell binding can signiﬁ-
cantly aﬀect the availability of compounds in vitro and
thus their toxic potencies and toxic equivalency factors.
In addition it was also reported that the presence of albu-
min of variable concentrations in medium greatly inﬂu-
ences the toxic potency of MeHg (Seibert et al., 2002).
This may be due to the presence of extra binding sites
which can reduce the eﬀective dose at the primary toxicity
targets. The cell density-dependent production of ROS has
also been reported by previous studies using diﬀerent
Table 1
Cell density dependent MeHg accumulation in C6-glial and B35-neuronal
cell lines as measured by 14C radiolabeled MeHg at 10 lM MeHg for
50 min
Cell type Day 3 Day 4
C6-glial 2048 ± 231c 5485 ± 755a
B35-neuronal 1499 ± 180d 3076 ± 426b
Values are expressed as ng Hg/mg protein, mean ± standard deviation.
Experiments were conducted in eight replications for each cell type. The
superscripts (a, b, c, and d) not showing common letters are signiﬁcantly
diﬀerent (p < 0.05) from each other. Values were corrected for protein
content in each well.
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models such as ﬁbroblasts (Pani et al., 2000), granulocytes
(Rosenkranz et al., 1992) and neural precursor cells (Limoli
et al., 2004). It has been reported by Zurgil et al. (1996) that
cell density related diﬀerences result in diﬀerences in cell
cycle which lead to changes in intracellular environment
such as changes in membrane ﬂuidity. They reported that
in T-lymphocyte Jurkat cell line, at highest cell density
the resting phase (G0/G1) predominated whereas at low cell
density the S or G2/M phase was predominant. Therefore,
the diﬀerences in cell cycle or dilution of eﬀective dose at
high cell density can be responsible for increased ROS pro-
duction at day 3 with 10 lM MeHg dose in both the cell
lines. The decreased production of ROS in C6 cells at
25 lM MeHg dose at day 3 as compared to day 4 could
be due to increased eﬀective dose at low cell density result-
ing in increased cytotoxicity and loss of the dye. The non-
diﬀerential production of ROS in B35 cells at 25 lMMeHg
dose at day 3 vs. day 4 could be due to the ability of this
cell type to upregulate the GSH content resulting in
decreased cytotoxicity. Therefore, changes in the intracellu-
lar environment may play a crucial role in the generation of
ROS detected by the DCF signal.
In cell culture uptake studies of compounds which are
sparingly water soluble and strongly bound to proteins,
the diﬀerentiation between the compounds being attached
to the surface of the cells from what is actually inside the
cell is diﬃcult. Moreover, the extensive washing procedures
may cause the cells to release the compound which has
been accumulated inside the cells during the assay. There-
fore, for the present study we measure the cell-associated
MeHg which represents the MeHg associated to cellular
protein structures. For MeHg, the uptake into the cells is
both an active, energy dependent (e.g. MeHg-cystein) as
well as passive uptake (e.g. MeHgCl) depending on the
Hg species (Aschner et al., 1990; Kerper et al., 1992; Wang
et al., 2000). Eﬀects of any unspeciﬁc binding of 14C-radio-
labeled MeHg in the culture well were prevented by wash-
ing the cells with cold Hepes buﬀer prior to solubilization
in NaOH. For both C6 and B35 cells, the cell associated-
MeHg was saturated after 60 min of exposure at doses
ranging from 1 to 10 lM MeHg (data not shown). The
increased cell associated-MeHg in C6 cells as compared
to B35 cells explains the increased production of ROS in
C6 cells. However, the increased cell associated-MeHg at
day 4 when compared to day 3 did not correlate with the
cell density dependent diﬀerences in MeHg-induced ROS.
This could be due to the presence of extra binding sites
at high cell density resulting in reduction of eﬀective dose.
The concentration dependent increase in cell associated-
MeHg at 30 and 50 min intervals for both the cell lines cor-
related with the MeHg-induced ROS eﬀects. However, the
changes in cell-associated MeHg at diﬀerent exposure con-
ditions did not always correlate with the ROS production.
The authors do not have an explanation for this phenom-
enon. This further highlights the importance of using con-
sistent cell densities and exposure conditions when
estimating ROS from the DCF signal.
Taken together, our study establishes that concentration,
time and cell density eﬀectively contributes to MeHg-
induced ROS generation. Therefore, optimum concentra-
tion, exposure time and consistent cell densities should be
of prime consideration while estimating the ﬂuorescent
DCF signal for studying ROS-induced neurotoxicity.
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Abstract
Methyl mercury (MeHg) is highly neurotoxic and may lead to numerous neurodegenerative disorders. In this study, we investigated the role of
glutathione (GSH) and reactive oxygen species (ROS) in MeHg-induced neurotoxicity, using primary cell cultures of cerebellar neurons and
astrocytes. To evaluate the effect of GSH on MeHg-induced cytotoxicity, ROS and GSH were measured using the ﬂuorescent indicators chloro
methyl derivative of di-chloro di-hydro ﬂuorescein diacetate (CMH2DCFDA) and monochlorobimane (MCB). Cell-associated MeHg was
measured with 14C-radiolabeled MeHg. Mitochondrial dehydrogenase activity was detected by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide]. MTT timeline study was also performed to evaluate the effects of both the concentration and duration of MeHg exposure.
The intracellular GSH content was modiﬁed by pretreatment with N-acetyl cysteine (NAC) or di-ethyl maleate (DEM) for 12 h. Treatment with
5 mMMeHg for 30 min led to signiﬁcant ( p < 0.05) increase in ROS and reduction ( p < 0.001) in GSH content. Depletion of intracellular GSH by
DEM further increased the generation of MeHg-induced ROS in both cell cultures. Conversely, NAC supplementation increased intracellular GSH
and provided protection against MeHg-induced oxidative stress in both cell cultures. MTT studies also conﬁrmed the efﬁcacy of NAC
supplementation in attenuating MeHg-induced cytotoxicity. The cell-associated MeHg was signiﬁcantly ( p < 0.02) increased after DEM
treatment. In summary, depletion of GSH increases MeHg accumulation and enhances MeHg-induced oxidative stress, and conversely,
supplementation with GSH precursor protects against MeHg exposure in vitro.
# 2006 Elsevier Inc. All rights reserved.
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1. Introduction
Methyl mercury (MeHg) is a potent neurotoxicant that
affects both the developing and mature central nervous system
(CNS). Several catastrophic epidemics resulting from con-
sumption of MeHg-adulterated food in Iraq (Bakir et al., 1973),
Pakistan, Guatemala and Ghana, or via environmental
contamination in Japan (Harada, 1995) have led to its
recognition as a ubiquitous environmental toxicant (for a
review, see Clarkson, 2002). The CNS damage caused by
MeHg is irreparable and different in adult brain versus fetal
brain (Lapham et al., 1995). Severe neurological disturbances,
such as paresthesia, ataxia, sensory and speech impairment, and
constriction of the visual ﬁeld are caused by MeHg poisoning
(Bakir et al., 1973; Harada, 1995; Elhassani, 1982). Con-
taminated ﬁsh from polluted areas, vaccines and dental
amalgams also pose as a potential source of Hg exposure in
humans (Clarkson et al., 2003). MeHg has a high association
constant (15 < pKa < 23) for sulfhydryl (SH) groups (Carty
and Malone, 1979). It can react with any SH-group leading to
conformational changes and thus inhibition of many enzymes.
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However, all signs and symptoms of toxicity in adults are
conﬁned mostly to the nervous system where it affects
primarily the granule layer of the cerebellum and the visual
cortex of the cerebrum (Takeuchi, 1982). Despite considerable
scientiﬁc efforts, the reason for this selective degeneration of
the nervous system has not been satisfactorily explained.
The adult human brain consumes >20% of the oxygen
utilized by the body although it comprises only 2% of the body
weight, indicating that ROS are generated at high rates during
oxidative metabolism of the brain (Dringen et al., 2000; Clarke
and Sokoloff, 1999). ROS can be detected by the
CMH2DCFDA dye as its oxidation yields a ﬂuorescent
product, 20,70-dichloroﬂuorescein (DCF), which is retained
inside the cell (Shanker et al., 2004). Antioxidants provide
cellular defense against ROS, with GSH constituting the most
important and abundant component (Cooper, 1997). Both
neurons and astrocytes contain GSH, which is involved in the
disposal of exogenous peroxides by acting as a co-substrate in
a reaction catalyzed by GSH peroxidase (GPx) (Eklow et al.,
1984;Wendel et al., 1980). However, astrocytes contain higher
concentrations of GSH than neurons (Kranich et al., 1996;
Sagara et al., 1993). The astrocytes provide precursor
molecules, e.g., cysteine, to neurons for GSH synthesis
(Shanker and Aschner, 2001; Sagara et al., 1993). The
availability of cysteine from glial cells becomes rate limiting
for synthesis of neuronal GSH (Kranich et al., 1998; Wang and
Cynader, 2000). The content of intracellular free thiols and the
subcellular compartmentation of GSH could be determined by
MCB (Bellomo et al., 1997). The MCB can diffuse passively
across the plasma membrane into the cytoplasm where it binds
with the reduced form of GSH and other thiol-containing
proteins leading to formation of blue ﬂuorescent adducts
(Haugland, 1996). Previous studies on the mechanism of
MeHg have shown that MeHg toxicity leads to depletion of
GSH and generation of ROS (Sanfeliu et al., 2001; Yee and
Choi, 1996). Several reports have implicated a critical role of
GSH in modulating MeHg neurotoxicity (Choi et al., 1996;
Miura and Clarkson, 1993). However, it still remains unclear
whether the protection afforded by GSH is due to protection
against ROS generated by MeHg or by reduction of
intracellular concentration ofMeHg. The present investigation
addresses this issue by ﬁrstly, evaluating the effect of MeHg on
the content of GSH and ROS in neurons as well as astrocytes,
and secondly, by examining the effect of GSH modulation on
the accumulation of MeHg in both cell types. GSH content of
primary cultured cells can be modulated by variety of
treatments (Dringen, 2000). NAC or DEM were employed for
GSH modulation in the present study. DEM depletes cellular
GSH by forming adducts with the thiol groups. DEM has been
reported to cause high mortality in HgCl2 treated rats (Baggett
and Berndt, 1986). NAC is a source of thiol groups and
scavenger of free radicals such as H2O2 and OH
 (Aruoma
et al., 1989). Previous studies have indicated the effectiveness
of NAC as an antidote against MeHg poisoning (Ballatori
et al., 1998; Koh et al., 2002). The present study attempts to
resolve the ambiguity concerning the cellular selectivity
exhibited by MeHg.
2. Materials and methods
2.1. Materials
Twenty-four-well plastic tissue culture plates were
purchased from Falcon (Becton Dickinson Labware). Fetal
calf serum (FCS) was acquired from Seralab Ltd. (Sussex,
UK) and culture medium was acquired from GIBCO BRL,
Life Technologies (Roskilde, Denmark). The ﬂuorescent
indicator CMH2DCFDA was purchased from Molecular
Probes Inc. (Eugene, OR). NAC, DEM and MCB were
acquired from Sigma Aldrich (Norway). Radiolabeled 14C-
MeHg (Cat. no. ARC-1302) was purchased from American
Radiolabeled Chemicals Inc. (St. Louis, MO, USA). MeHgCl
(Cat. No 23308) was purchased from K&K Laboratories
(Plainview, NY, USA). All other chemicals were of analytical
grade.
2.2. Animals
NMRI mice were purchased from Møllegaard Breeding
Center (Copenhagen, Denmark). Prior to experiments the
animals had free access to food and water and were kept
under constant conditions of temperature (22 8C), humidity
(60%) and 12 h light/dark cycles. The animals were handled
in compliance with the NTNU Animal Care and Use
Committee.
2.3. Cell cultures
Cerebellar astrocytes were prepared as described earlier
(Hertz et al., 1989). Brieﬂy, cerebella obtained from 7-day-old
mice were passed through Nitex nylon netting (80 mm pore
size) into Dulbecco’s minimum essential medium (DMEM)
containing 20% (v/v) fetal calf serum (FCS). The cell
suspension was then plated at a density of 0.5 cerebella per
24-well culture plate, which was coated previously with poly-D-
lysine. Medium was changed 2 days after plating and
subsequently twice a week, gradually decreasing the FCS
concentration to 10%. At 14 days in culture, dibutyryl-cAMP
was added to the medium for 1 week to promote the
morphological differentiation of astrocytes. Cells were used
for the experiment 21 days post-isolation and the cultures were
80% conﬂuent by this time.
Primary cultures of cerebellar neuronal cells were prepared
from cerebella of 7-day-old mice according to the method
described by Schousboe et al., 1989. Brieﬂy, mild trypsinized
cerebella were triturated in a DNase solution containing a
soybean trypsin inhibitor. The cells were suspended in
DMEM (19 mM KCl, 31 mM glucose, and 0.2 mM gluta-
mine) supplemented with 50 mM kainic acid, p-aminobenzo-
ate, insulin, penicillin, garamycin and 10% (v/v) FCS. Cells
were seeded at a density of (0.8  106 cells/ml) in 24-
multiwell plate, which were previously coated with poly-D-
lysine and incubated in a humidiﬁed 5% CO2/95% air
atmosphere at 37 8C. Neuronal cultures were used 1 week
post-isolation.
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notable ( p < 0.001) at 10 mM concentration and at 60 min
exposure for both cell types. A slight increase in MTT activity
was observed in astroglial cultures at 1 mM concentration and
at 15 min interval, which may indicate inherent protective
mechanisms. At any particular concentration and time interval,
cerebellar neurons were more susceptible to MeHg-induced
reduction in MTT activity than cerebellar astrocytes. At 5 mM
MeHg concentration for 30 min there was a 41% ( p < 0.001)
reduction in mitochondrial activity in neurons (Fig. 6) as
compared to 25% ( p < 0.05) reduction in astrocytes (Fig. 6).
4. Discussion
The present study addresses the role of GSH in differential
cytotoxic effects of MeHg in cerebellar neurons and astrocytes.
It determined that depletion of GSH increases the intracellular
concentration of MeHg in both cell types and therefore
inﬂuences the generation of ROS.
4.1. GSH modiﬁcation and ROS generation
MCB ﬂuorescence studies indicated that MeHg causes a
depletion in GSH content both in neuronal and astroglial cells,
which is in accordance with the previous studies (Saraﬁan and
Verity, 1990). It has been reported that NAC is an acetylated
analog of cysteine, which easily crosses the cell membrane and
is rapidly deacetylated inside the cell to become available for
GSH synthesis (Zafarullah et al., 2003). Our present data shows
that NAC was effective in preventing MeHg-induced GSH loss
in both cell cultures. In the control cells, NAC did not increase
the GSH level. However, after MeHg exposure NAC-pretreated
cells more readily met the increased demand for reduced GSH.
In contrast, loss of protective thiol groups by DEM further
augmented MeHg-induced loss of GSH. The average control
MCB values indicated that cerebellar astrocytes contained a
greater supplement of GSH than cerebellar neurons, which is
consistent with previous observation (Raps et al., 1989). The
present study demonstrates that neurons were more vulnerable
to MeHg-induced GSH depletion, indicating that GSH status
likely represents a key factor in the neuropathologic and cell
speciﬁc effects of MeHg.
Previous in vivo studies in rodent cerebellum and in vitro
studies in sub cellular fractions (Ali et al., 1992) in cell lines
(Saraﬁan et al., 1994) and primary cultures (Shanker et al.,
2004; Shanker and Aschner, 2003) have indicated that ROS are
mediators of MeHg-induced neurotoxicity. In addition, GSH
modulators have been reported to inﬂuence MeHg-induced
ROS in cerebellar astrocytes (Shanker et al., 2005). The present
study is in accordance with the previous studies, as we also
observed an increase in CMH2DCFDA ﬂuorescence in both cell
types with MeHg treatment. The results indicate that depletion
of cellular thiols by DEM induced and augmented MeHg-
induced accumulation of ROS. CMH2DCFDA measurements
indicated that neurons were more affected by MeHg treatment
as well as DEM induced ROS than astrocytes. MeHg-induced
ROSwas however, ameliorated with NAC treatment in both cell
cultures as indicated by decrease in CMH2DCFDA ﬂuores-
cence. Thus, GSH modulators affect MeHg-induced ROS
generation differentially in neurons and astrocytes.
4.2. MeHg accumulation
The unique aspect of the present study is that intracellular
GSH concentrations were directly correlated both in astrocytes
and neurons not only with MeHg-induced oxidative stress, but
also with cell-associated MeHg content. Since the demethyla-
tion of MeHg is a slow process (Magos et al., 1985) it will not
occur at any signiﬁcant rate during the 30 min incubation
period used in the present study and the 14C measurements thus
represent MeHg content (Simmons-Willis et al., 2002; Morken
et al., 2005; Koh et al., 2002).
The GSHmodulator-DEM increasedMeHg accumulation in
both cell types, indicating that depletion of thiol groups
predisposes the cells to MeHg-induced cytotoxicity. However,
the tendency of DEM to increase Hg accumulation was more
considerable in neurons ( p < 0.001) versus astrocytes
( p < 0.02). It was also observed that cell associated-MeHg
was approximately ﬁve times higher in neurons than astrocytes.
These data suggest that cerebellar neurons were more sensitive
to thiol depletion and MeHg-induced neurotoxicity than
astrocytes. No signiﬁcant differences were observed in either
cell type between MeHg group and NAC pretreated MeHg
group. The non-signiﬁcant increase in cell associated-MeHg
with NACmay be due to binding of MeHg to the cysteine group
of NAC, which may prevent binding of MeHg to other sensitive
target sites. Previous studies have indicated that MeHg uptake
increases when it is present as L-cysteine complex but not as D-
cysteine, NAC, penicillamine or GSH complexes (Wang and
Clarkson, 2000; Simmons-Willis et al., 2002) suggesting the
active role of L-neutral amino acid transporter in MeHg uptake.
The MeHg-thiol interactive chemistry is responsible for
variable accumulation of MeHg. Increased MeHg accumula-
tion increases MeHg-induced toxicity as indicated by the more
pronounced production of ROS, depletion of GSH and
reduction of MTT, when both neurons and astrocytes are co-
incubated with MeHg and DEM.
4.3. Effects on mitochondrial function (MTT-reduction)
The MTT data supports MeHg’s differential effects in
neurons versus astrocytes. Cerebellar neurons are more
sensitive to MeHg than cerebellar astrocytes, consistent with
previous reports (Sanfeliu et al., 2001). Our present data asserts
that this cellular speciﬁcity reﬂects increased neuronal
accumulation of MeHg in neurons versus astrocytes. Previous
studies have indicated the protective effects of NAC against
thimerosal (James et al., 2005) and MeHg hydroxide (Gatti
et al., 2004) induced reduction of MTT activity in different cell
lines. Effectiveness of amino acids and antioxidants, such as
cysteine and GSH against MeHg-induced decrease in MTT
activity has also been previously reported in primary cell
cultures (Sanfeliu et al., 2001). Our present MTT data
corroborates these studies and demonstrates the efﬁcacy of
NAC supplementation in primary neuronal and astroglial cell
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cultures. In both cell types, DEM and MeHg treatment induced
a reduction in MTT activity. The combined effect of MeHg and
DEM was, however, synergistic and not additive. Previous
studies have proposed that decrease in intracellular GSH by
DEM causes inhibition of MeHg efﬂux from brain endothelial
cells (Kerper et al., 1996). Our present data shows that DEM
causes increase in intracellular concentration of MeHg
available for reduction in MTT activity.
In summary, the present study demonstrates that main-
tenance of adequate GSH levels protects against MeHg-induced
oxidative stress in primary cell cultures of neurons and
astrocytes. The difference in the GSH status provides a possible
explanation for the differences between MeHg-induced
neuronal and astroglial toxicity. The limited GSH availability
might be one of the mechanisms responsible for making
neurons more susceptible to MeHg toxicity versus astrocytes. It
afﬁrms that modulation of GSH levels effectively change the
intracellular concentration of MeHg which in turn will alter the
risk of MeHg-induced oxidative stress.
Acknowledgments
The authors gratefully acknowledge the excellent technical
assistance of Bente Urfjell and Lars Evje.
References
Ali SF, LeBel CP, Bondy SC. Reactive oxygen species formation as a biomarker
of methylmercury and trimethyltin neurotoxicity. Neurotoxicology
1992;13:637–48.
Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-
acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical,
superoxide, and hypochlorous acid. Free Radic Biol Med 1989;6:
593–7.
Baggett JM, Berndt WO. The effect of depletion of non-protein sulfhydryls by
diethyl maleate plus buthionine sulfoximine on renal uptake of mercury in
the rat. Toxicol Appl Pharmacol 1986;83:556–62.
Bakir F, Damluji SF, min-Zaki L, Murtadha M, Khalidi A, al-Rawi NY, Tikriti
S, Dahahir HI, Clarkson TW, Smith JC, Doherty RA. Methylmercury
poisoning in Iraq. Science 1973;181:230–41.
Ballatori N, Lieberman MW, Wang W. N-acetylcysteine as an antidote in
methylmercury poisoning. Environ Health Perspect 1998;106:267–71.
Bellomo G, Palladini G, Vairetti M. Intranuclear distribution, function and fate
of glutathione and glutathione-S-conjugate in living rat hepatocytes studied
by ﬂuorescence microscopy. Microsc Res Tech 1997;36:243–52.
Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a
tetrazolium-based semiautomated colorimetric assay: assessment of radio-
sensitivity. Cancer Res 1987;47:943–6.
Carty AJ, Malone SF. The chemistry of mercury in biological systems. In:
Nrigau JO, editor. The Biogeochemistry of Mercury in the Environment.
Amsterdam: Elsevier/North-Holland Biomedical Press; 1979. p. 433–79.
Choi BH, Yee S, Robles M. The effects of glutathione glycoside in methyl
mercury poisoning. Toxicol Appl Pharmacol 1996;141:357–64.
Clarke DD, Sokoloff L. Circulation and energy metabolism of the brain. In:
Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, editors. Basic
Neurochemistry: Molecular, Cellular and Medical Aspects. Philadelphia:
Lippincott-Raven; 1999. p. 637–69.
Clarkson TW. The three modern faces of mercury. Environ Health Perspect
2002;110:11–23.
Clarkson TW, Magos L, Myers GJ. The toxicology of mercury-current expo-
sures and clinical manifestations. N Engl J Med 2003;349:1731–7.
Cooper AJL. Glutathione in the brain: disorders of glutathione metabolism. In:
Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Kunk LM, editors. The
Molecular and Genetic Basis of Neurological Disease. Boston: Butterworth-
Heinemann; 1997. p. 1195–230.
Dahlin KL, Bohlin K, Strindlund J, Ryrfeldt A, Cotgreave IA. Amitriptyline-
induced loss of tight junction integrity in a human endothelial smooth
muscle cell bi-layer model. Toxicology 1999;136:1–13.
Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol
2000;62:649–71.
Dringen R, Gutterer JM, Hirrlinger J. Glutathione metabolism in brain meta-
bolic interaction between astrocytes and neurons in the defense against
reactive oxygen species. Eur J Biochem 2000;267:4912–6.
Eklow L, Moldeus P, Orrenius S. Oxidation of glutathione during hydroper-
oxide metabolism. A study using isolated hepatocytes and the glutathione
reductase inhibitor 1,3-bis(2-chloroethyl)-1-nitrosourea. Eur J Biochem
1984;138:459–63.
Elhassani SB. The many faces of methylmercury poisoning. J Toxicol Clin
Toxicol 1982;19:875–906.
Gatti R, Belletti S, Uggeri J, Vettori MV, Mutti A, Scandroglio R, Orlandini G.
Methylmercury cytotoxicity in PC12 cells is mediated by primary glu-
tathione depletion independent of excess reactive oxygen species genera-
tion. Toxicology 2004;204:175–85.
Harada M. Minamata disease: methylmercury poisoning in Japan caused by
environmental pollution. Crit Rev Toxicol 1995;25:1–24.
Haugland RP. Handbook of Fluorescent Probes and Research Chemicals.
Eugene: Molecular Probes Inc.; 1996.
Hertz L, Juurlink BHJ, Hertz E, Fosmark H, Schousboe A. Preparation of
primary cultures of mouse (rat) cerebellar granule cells. In: Shahar A, De
Vellis J, Vernadakis A, Haber B, editors. A Dissection and Tissue Culture
Manual for the Nervous System. New York: Alan R. Liss; 1989. p. 105–8.
James SJ, Slikker W, Melnyk S, New E, Pogribna M, Jernigan S. Thimerosal
neurotoxicity is associated with glutathione depletion: protection with
glutathione precursors. Neurotoxicology 2005;26:1–8.
Kerper LE, Mokrzan EM, Clarkson TW, Ballatori N. Methylmercury efﬂux
from brain capillary endothelial cells is modulated by intracellular glu-
tathione but not ATP. Toxicol Appl Pharmacol 1996;141:526–31.
Koh AS, Simmons-Willis TA, Pritchard JB, Grassl SM, Ballatori N. Identiﬁca-
tion of a mechanism by which the methylmercury antidotes N-acetylcys-
teine and dimercaptopropanesulfonate enhance urinary metal excretion:
transport by the renal organic anion transporter-1. Mol Pharmacol
2002;62:921–6.
Kranich O, Dringen R, Sandberg M, Hamprecht B. Utilization of cysteine and
cysteine precursors for the synthesis of glutathione in astroglial cultures:
preference for cystine. Glia 1998;22:11–8.
Kranich O, Hamprecht B, Dringen R. Different preferences in the utilization of
amino acids for glutathione synthesis in cultured neurons and astroglial cells
derived from rat brain. Neurosci Lett 1996;219:211–4.
Lapham LW, Cernichiari E, Cox C, Myers GJ, Baggs RB, Brewer R, Shamlaye
CF, Davidson PW, Clarkson TW. An analysis of autopsy brain tissue from
infants prenatally exposed to methymercury. Neurotoxicology 1995;16:
689–704.
Lowry O, Rosenbrough NJ, Farr AJ. Protein measurement with the folin phenol
reagent. J Biol Chem 1951;193:265–75.
Magos L, Brown AW, Sparrow S, Bailey E, Snowden RT, Skipp WR. The
comparative toxicology of ethyl- and methylmercury. Arch Toxicol 1985;
57:260–7.
Miura K, Clarkson TW. Reduced methylmercury accumulation in a methyl-
mercury-resistant rat pheochromocytoma PC12 cell line. Toxicol Appl
Pharmacol 1993;118:39–45.
Morken TS, Sonnewald U, Aschner M, Syversen T. Effects of methylmercury
on primary brain cells in mono and co-culture. Toxicol Sci 2005;87:
169–75.
Raps SP, Lai JC, Hertz L, Cooper AJ. Glutathione is present in high concentra-
tions in cultured astrocytes but not in cultured neurons. Brain Res
1989;493:398–401.
Sagara JI, Miura K, Bannai S. Maintenance of neuronal glutathione by glial
cells. J Neurochem 1993;61:1672–6.
Sanfeliu C, Sebastia J, Ki SU. Methylmercury neurotoxicity in cultures of
human neurons, astrocytes, neuroblastoma cells. Neurotoxicology 2001;22:
317–27.
P. Kaur et al. / NeuroToxicology 27 (2006) 492–500 499
Saraﬁan T, Verity MA. Oxidative mechanisms underlying methyl mercury
neurotoxicity. Int J Devl Neurosci 1990;9:147–53.
Saraﬁan TA, Vartavarian L, Kane DJ, Bredesen DE, Verity MA. bcl-2 expres-
sion decreases methyl mercury-induced free-radical generation and cell
killing in a neural cell line. Toxicol Lett 1994;74:149–55.
Schousboe A, Meier E, Drejer J, Hertz L. Preparation of primary cultures of
mouse (rat) cerebellar granule cells. In: Shahar A, De Vellis J, Vernadakis A,
Haber B, editors. A Dissection and Tissue Culture Manual for the Nervous
System. New York: Alan R. Liss; 1989. p. 183–6.
Shanker G, Aschner JL, Syversen T, Aschner M. Free radical formation in
cerebral cortical astrocytes in culture induced by methylmercury. Mol Brain
Res 2004;128:48–57.
Shanker G, Aschner M. Identiﬁcation and characterization of uptake systems
for cystine and cysteine in cultured astrocytes and neurons: evidence for
methylmercury-targeted disruption of astrocyte transport. J Neurosci Res
2001;66:998–1002.
Shanker G, Aschner M. Methylmercury-induced reactive oxygen species
formation in neonatal cerebral astrocytic cultures is attenuated by antiox-
idants. Mol Brain Res 2003;110:85–91.
Shanker G, Syversen T, Aschner JL, Aschner M. Modulatory effect of glu-
tathione status and antioxidants on methylmercury-induced free radical
formation in primary cultures of cerebral astrocytes. Mol Brain Res 2005;
137:11–22.
Simmons-Willis TA, Koh AS, Clarkson TW, Ballatori N. Transport of a
neurotoxicant by molecular mimicry: the methylmercury-L-cysteine com-
plex is a substrate for human L-type large neutral amino acid transporter
LAT 1 and LAT 2. Biochem J 2002;367:239–46.
Takeuchi T. Pathology of Minamata disease. With special reference to its
pathogenesis. Acta Pathol Jpn 1982;32:73–99.
Wang W, Clarkson TW, Ballatori N. Gamma-glutamyl transpeptidase and L-
cysteine regulate methylmercury uptake by HepG2 cells, a human hepatoma
cell line. Toxicol Appl Pharmacol 2000;168:72–8.
Wang XF, Cynader MS. Astrocytes provide cysteine to neurons by releasing
glutathione. J Neurochem 2000;74:1434–42.
Wendel A. Glutathione peroxidase. In: Jacoby WB, editor. Enzymatic Basis of
Detoxication. New York: Academic Press; 1980. p. 333–56.
Yee S, Choi BH. Oxidative stress in neurotoxic effects of methylmercury
poisoning. Neurotoxicology 1996;17:17–26.
Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-
acetylcysteine actions. Cell Mol Life Sci 2003;60:6–20.
P. Kaur et al. / NeuroToxicology 27 (2006) 492–500500

Paper III

Toxicology 230 (2007) 164–177
Role of glutathione in determining the differential sensitivity
between the cortical and cerebellar regions towards
mercury-induced oxidative stress
Parvinder Kaur a, Michael Aschner b, Tore Syversen a,∗
a Department of Neuroscience, Norwegian University of Science and Technology, N-7489 Trondheim, Norway
b Department of Pediatrics and Pharmacology, and the Kennedy Center, Vanderbilt University Medical Center,
B-3307 Medical Center North, 1162 21st Avenue, Nashville, TN 37232-2495, USA
Received 5 September 2006; received in revised form 6 November 2006; accepted 9 November 2006
Available online 19 November 2006
Abstract
Certain discrete areas of the CNS exhibit enhanced sensitivity towards MeHg. To determine whether GSH is responsible for
this particular sensitivity, we investigated its role in MeHg-induced oxidative insult in primary neuronal and astroglial cell cul-
tures of both cerebellar and cortical origins. For this purpose, ROS and GSH were measured with the ﬂuorescent indicators,
CMH2DCFDA and MCB. Cell associated-MeHg was measured with 14C-radiolabeled MeHg. The intracellular GSH content was
modiﬁed by pretreatment with NAC or DEM. For each of the dependent variables (ROS, GSH, and MTT), there was an overall
signiﬁcant effect of cellular origin, MeHg and pretreatment in all the cell cultures. A trend towards signiﬁcant interaction between
origin×MeHg× pretreatment was observed only for the dependent variable, ROS (astrocytes p= 0.056; neurons p= 0.000). For
GSH, a signiﬁcant interaction between origin×MeHg was observed only in astrocytes (p= 0.030). The cerebellar cell cultures
were more vulnerable (astrocytesmean = 223.77; neuronsmean = 138.06) to ROS than the cortical cell cultures (astrocytesmean = 125.18;
neuronsmean = 107.91) for each of the tested treatments. The cell associated-MeHg increased when treated with DEM, and the cere-
bellar cultures varied signiﬁcantly from the cortical cultures. Non-signiﬁcant interactions between origin×MeHg× pretreatment
for GSH did not explain the signiﬁcant interactions responsible for the increased amount of ROS produced in these cultures. In
summary, although GSH modulation inﬂuences MeHg-induced toxicity, the difference in the content of GSH in cortical and cere-
bellar cultures fails to account for the increased ROS production in cerebellar cultures. Hence, different approaches for the future
studies regarding the mechanisms behind selectivity of MeHg have been discussed.
© 2006 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Methylmercury (MeHg) is an important environmen-
tal neurotoxicant capable of posing risks to human
health (Aschner and Syversen, 2005). It is a hazardous
trace metal that is released into the environment from
both natural and anthropogenic sources (EPA, 1997;
ATSDR, 1999). MeHg accumulates in aquatic organ-
isms and biomagniﬁes through the foodweb from10,000
to 100,000 times (EPA, 1997; Wiener et al., 2003).
Thus, the major dietary route of human exposure to
MeHg is via the ingestion of seafood for adults and
via maternal milk for infants (Manfroi et al., 2004).
Major human epidemics in Japan (Takeuchi, 1982; Eto,
2000) and Iraq (Bakir et al., 1973) have established the
toxicity of MeHg in the nervous system. It is critical
that we ascertain the neurobiological processes which
may be detrimentally affected by this environmental
agent.
MeHghas a high afﬁnity for binding to all thiol groups
(Hughes, 1957), indicating that more than one mecha-
nism may contribute to the expression of MeHg-induced
neurotoxicity. However, the existence of multiple mech-
anisms of toxicity are difﬁcult to reconcile with the
speciﬁc pattern of neurological damage associated with
MeHg, such as in the cerebellar granule cell layer and
in the calcarine region of the occipital cortex in humans
(Hunter and Russell, 1954; Choi et al., 1978; Takeuchi,
1982; Eto, 1997) and in rodent brains (Nagashima,
1997). The mechanisms associated with enhanced sen-
sitivity in these areas of the CNS remain unknown.
Cerebellar granule cells are predominately glutamater-
gic, whereas cortical neurons are mainly GABAergic,
while expressing glutamate receptors also (Yu et al.,
1984; Hertz and Schousboe, 1987). Major mechanisms
of MeHg neurotoxicity involve the spontaneous release
of glutamate and GABA in neurons (Atchison and Hare,
1994) and the inhibition of the uptake of glutamate and
GABA in astrocytes (Aschner et al., 2000) and in cortical
slices of adult rat brains (Farina et al., 2003). Neuronal
dysfunction has been proposed to be secondary to dis-
turbances in astrocytes (Allen et al., 2001). However, the
sparing of Purkinje cells and the sensitivity of granule
cells in the cerebellum cannot be attributable solely to
the vulnerability of cerebellar astrocytes towards MeHg,
for under these circumstances, both Purkinje and granule
cells would be expected to respond in a similar fashion.
Therefore, it is important to identify the unique charac-
teristics of cells that express high resistance to MeHg.
Molecular oxygen is essential for many biological
events associated with aerobic metabolism, and this
results in the constant formation of ROS (Powis et
al., 1995). Conversely, GSH is the most abundant thiol
tripeptide present in mammalian cells for scavenging
reactive oxygen species (Roberts et al., 1980; Fang et
al., 2002). MeHg causes a reduction in the amount of
intracellular GSH (Miura and Clarkson, 1993; Saraﬁan
et al., 1994; Choi et al., 1996; Gatti et al., 2004) and
the augmentation of ROS formation (Ali et al., 1992;
Yee and Choi, 1996; Sorg et al., 1998; Saraﬁan, 1999;
Gasso et al., 2001; Sanfeliu et al., 2001; Shanker and
Aschner, 2003). However, little is known concerning this
relationship in speciﬁc anatomical regions of the brain.
Previous work from our laboratory (Kaur et al., 2006)
prompted us to investigate whether GSH is responsi-
ble for the differences induced by MeHg in cerebellar
and cortical cultures. MCB has been previously used
for measuring GSH levels in tissue (Kamencic et al.,
2000), glia (Chatterjee et al., 1999, 2000), neuroblastoma
and neuronal cultures (Tauskela et al., 2000; Sebastia
et al., 2003). MCB is a cell permeable, nonﬂuorescent
bimane which conjugates to GSH, forming a ﬂuorescent
compound with the help of the enzyme, glutathione-
S-transferase. Application of CMH2DCFDA dye for
measuring ROS (Liu et al., 2001; Shanker et al., 2004;
Shimazawa et al., 2005) is more useful than other DCF
dyes (Carter et al., 1994; Oyama et al., 1994), since
the trapped ﬂuorescent adduct inside the cell is better
retained in live cells.
The present study was designed to assess the dif-
ferences between the oxidative effects of MeHg in
cerebellar and cortical primary cultures of neurons and
astrocytes from mice brains. This comparative approach
allowed us to test the effect of differences in GSH con-
tent on the generation of MeHg-induced ROS in these
regions of the brain.
2. Materials and methods
2.1. Materials
Twenty-four-well plastic tissue culture plates were pur-
chased from Falcon (Becton Dickinson Labware). FCS used
for cerebellar cultures and cortical astrocytes was acquired
from Seralab Ltd. (Sussex, UK). Dialyzed serum for cultur-
ing cortical neurons was obtained from GIBCO BRL, Life
Technologies (Roskilde, Denmark). The culture medium was
acquired fromSigmaAldrich (Germany). The ﬂuorescent indi-
cator CMH2DCFDA was purchased from Molecular Probes,
Inc. (Eugene, OR). NAC, DEM and MCB were acquired
from Sigma Aldrich (Norway). Radiolabeled 14C-MeHg (Cat.
no. ARC-1302) was purchased from American Radiolabeled
Chemicals Inc. (St. Louis, MO, USA). MeHgCl (Cat. no.
23308)was purchased fromK&KLaboratories (Plainview,NY,
USA). All other chemicals were of analytical grade.
170 P. Kaur et al. / Toxicology 230 (2007) 164–177
Fig. 5. Cellular ROS detected by CMH2DCFDA ﬂuorescence in primary astroglial cultures from the cerebellum and the cerebrum. Results are
expressed as mean± standard deviation (n= 8 replicates for each cell type in two independent experiments). The letters (a, b, and c) indicate the
interaction between MeHg× pretreatment and data not showing common letters are signiﬁcantly different from each other (p= 0.000); #signiﬁcant
difference between the cerebellum and the cerebrum for each type of treatment (origin×MeHg p= 0.007; origin×MeHg× pretreatment p= 0.056).
Values were corrected for protein content in each well and determined as a percentage of ﬂuorescence with respect to control cells.
action between origin×MeHg (astrocytes p= 0.007;
neurons p= 0.000, Table 1) indicated that the amount
of ROS produced in the cerebellar cultures varied
signiﬁcantly from the cortical cultures. Interaction
between origin×MeHg× pretreatment (astrocytes
p= 0.056; neurons p= 0.000) indicated that treatment
with MeHg resulted in the increased production of
ROS in cerebellar astrocytes and neurons from both
the cerebellum and the cortex with respect to the
control groups. This interaction also underlines that
cerebellar cultures exposed to MeHg produce more
ROS (astrocytesmean = 151.915; neuronsmean = 411.770)
than cortical cultures (astrocytesmean = 108.384;
neuronsmean = 133.729). In particular, ROS generated
by MeHg in cerebellar neurons varied signiﬁcantly
from ROS generated in the cortical neurons, and
this difference was sustained upon DEM treatment.
However, in astrocytes, an increase in the amount of
ROS was observed in the DEM-pretreated MeHg group
when compared to the MeHg group. The amount of
ROS generated in cerebellar cultures which were treated
with NAC and MeHg varied signiﬁcantly from the
amount of ROS generated in the cortical cultures. In
addition, for neurons, the NAC-pretreated MeHg group
varied from the MeHg group.
3.3. Depletion of GSH and ROS accumulation
induces cytotoxicity
Exposure to MeHg (5M) resulted in a reduction
of MTT activity in all of the cultures when compared
to the control (Fig. 7, astrocytes; Fig. 8, neurons).
Fig. 6. Cellular ROS detected by CMH2DCFDA ﬂuorescence in primary neuronal cultures from the cerebellum and the cerebrum. Results are
expressed as mean± standard deviation (n= 8 replicates for each cell type in two independent experiments). The letters (a and b) indicate the
interaction between MeHg× pretreatment, and data not showing common letters are signiﬁcantly different from each other (p= 0.000); #signiﬁcant
difference between the cerebellum and the cerebrum for each type of treatment (origin×MeHg× pretreatment p= 0.000). Values were corrected
for protein content in each well and determined as a percentage of ﬂuorescence with respect to control cells.
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Fig. 7. Cytotoxicity detected by reduction of MTT in primary astroglial cultures from the cerebellum and the cerebrum. Results are expressed as
mean± standard deviation (n= 8 replicates for each cell type in two independent experiments). The letters (a, b, c, and d) indicate the interaction
between MeHg× pretreatment, and data not showing common letters are signiﬁcantly different from each other (p= 0.000); #signiﬁcant difference
between the cerebellum and the cerebrum for each type of treatment (origin× pretreatment p= 0.000). Values are presented as a percentage of
activity in control cells.
The MTT activity was further reduced upon DEM and
MeHg treatment in all of the cultures when compared
to the DEM group as well as the MeHg group. For the
dependent variable, MTT, non-signiﬁcant interactions
between the origin×MeHg× pretreatment (Table 1)
were observed for both neurons and astrocytes. How-
ever, signiﬁcant interactions between the origin×MeHg
(neurons p= 0.000, Table 1) indicated that there was a
signiﬁcant difference in theMTT activity in cortical neu-
rons when compared to cerebellar neurons upon MeHg
treatment. No signiﬁcant difference in the MTT activity
was observed between cerebellar and cortical astrocytes
when treated with MeHg. However, we observed that
cortical astrocytes are more viable than cerebellar astro-
cytes when continuously exposed to a low dose of MeHg
during maturation (data not shown). Increased MTT
activity was observedwith NAC pretreatment in cerebel-
lar cultures as compared to cortical cultures. The MTT
activity in the NAC-pretreated MeHg group did not vary
signiﬁcantly from the MeHg group in any of the cell
cultures.
3.4. MeHg accumulation
Depletion of GSH with DEM treatment led to
increased MeHg accumulation in both cortical and
cerebellar cultures (Table 2). However, no signiﬁcant
changes were observed in cell associated-MeHg in NAC
pretreated cortical astrocytes and neurons from the cere-
bellum or the cortex when compared to the control.
The MeHg accumulation in cortical cultures treated
with either NAC or DEM differed signiﬁcantly from the
MeHg accumulation in the cerebellar cultures. It was
observed that cerebellar cultures accumulated MeHg to
a greater extent than cortical cultures when modiﬁed by
NAC or DEM.
Fig. 8. Cytotoxicity detected by the reduction of MTT in primary neuronal cultures from the cerebellum and the cerebrum. Results are expressed
as mean± standard deviation (n= 8 replicates for each cell type in two independent experiments). The letters (a, b, and c) indicate the interaction
between MeHg× pretreatment, and data not showing common letters are signiﬁcantly different from each other (p= 0.000); #signiﬁcant difference
between the cerebellum and the cerebrum for each type of treatment (origin×MeHg p= 0.003; origin× pretreatment p= 0.000). Values are presented
as a percentage of activity in control cells.
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Table 2
Effect of GSH modulators on MeHg accumulation in primary cultures of cerebellar and cortical origin as measured by 14C radiolabeled MeHg at
50min
Cell type Region MeHg MeHg+NAC MeHg+DEM
Astrocytes Cerebellar 1.06 ± 0.09 d 1.21 ± 0.22 bc 1.61 ± 0.25 a
Cortical 1.11 ± 0.14 cd 1.00 ± 0.14 d 1.32 ± 0.11 b
Neurons Cerebellar 1.37 ± 0.18 b 1.31 ± 0.20 b 1.55 ± 0.22 a
Cortical 1.04 ± 0.16 c 1.06 ± 0.24 c 1.34 ± 0.26 b
Values are expressed as gHg/mg protein, mean± standard deviation. Experiments were conducted in 15 replications for each cell types in three
independent experiments. The letters (a, b, c, and d) indicate the interaction between origin× pretreatment and data not showing common letters
are signiﬁcantly different from each other. Values were corrected for protein content in each well.
3.5. MTT timeline studies
A signiﬁcant effect of time and MeHg concentra-
tion (p= 0.000) was observed for astrocytes (Fig. 9)
from both the cortex and the cerebellum, which indi-
cated that an increase in MeHg concentration and
exposure time results in reduced mitochondrial activ-
ity. There was a signiﬁcant difference between the
control and 5 and 10M MeHg treated astrocytes
(p= 0.000). The timeline for astrocytes indicated that
the 15min interval varied signiﬁcantly from the 30min
(p= 0.018) and 60min (p= 0.000) intervals. How-
ever, there was a non-signiﬁcant interaction between
the origin×MeHg treatment (p= 0.078) in astrocytes.
For neurons (Fig. 10.), a signiﬁcant effect of ori-
gin, time and MeHg concentration (p= 0.000) was
observed. Additionally, a signiﬁcant interaction between
the origin×MeHg group (p= 0.000) as well as the
time×MeHg group (p= 0.003) was observed for neu-
rons. These signiﬁcant interactions indicated that the
cortical neurons varied from the cerebellar neurons
both at 5 and 10M concentrations of MeHg. The
time×MeHg interaction for neurons indicated that all
of the time intervals (15, 30 and 60min) varied sig-
niﬁcantly from each other. However, both neurons and
astrocytes demonstrated non-signiﬁcant interactions for
the origin×MeHg× time treatment.
3.6. Effect of biological material on MTT activity
The effect of two different cell concentrations on
MTT activity was observed (Table 3) in order to signify
the importance of optimal and consistent cell seeding
densities while comparing cells from different regions
for investigating MeHg cytotoxicity. The signiﬁcant
interaction between the origin×MeHg× cell density
for astrocytes (p= 0.002) indicated that theMTT activity
in cortical astrocytes treated with MeHg varied signiﬁ-
cantly from the MTT activity in MeHg treated cerebellar
astrocytes only at a lower cell density. Moreover, the
MTTactivity in cerebellar astrocytes at a low cell density
varied signiﬁcantly for the respective culture at a high
cell density. For neurons, the signiﬁcant differences for
the ﬁxed factors such as origin (p= 0.010), cell density
Fig. 9. Study of MTT timeline in primary cerebellar and cortical astrocytes. Results are expressed as mean± standard deviation (n= 4 replicates for
each cell type in two independent experiments) where ‘*’ indicates the signiﬁcant difference when compared to the control group (MeHg p= 0.000).
No signiﬁcant interaction between origin×MeHg and origin×MeHg× time was observed. Values were corrected for protein content in each well
and determined as a percentage of activity with respect to control cells.
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Fig. 10. Study of MTT timeline in primary cerebellar and cortical neurons. Results are expressed as mean± standard deviation (n= 4 replicates for
each cell type in two independent experiments) where ‘*’ indicates the signiﬁcant difference when compared to the control group (MeHg p= 0.000);
#signiﬁcant difference between the cerebellum and the cerebrum for each type of treatment (origin×MeHg p= 0.000). No signiﬁcant interaction
between origin×MeHg× time was observed. Values were corrected for protein content in each well and determined as a percentage of activity
with respect to control cells.
Table 3
Effect of different cell densities on MTT activity in cerebellar and cortical cultures
Cell type Region Low cell density High cell density
Control 5M MeHg Control 5M MeHg
Astrocytes Cerebellar 100 ± 10 a 70 ± 8 d 100 ± 3 ab 84 ± 2 c
Cortical 100 ± 8 a 90 ± 5 bc 100 ± 1 a 85 ± 4 c
Neurons Cerebellar 100 ± 1 63 ± 4 100 ± 5 72 ± 5
Cortical 100 ± 3 50 ± 6 100 ± 13 61 ± 6
Low cell density = 0.5 cerebella or cerebra/24-well culture plate (astrocytes); 0.8× 106 cells/2 cm2 (neurons) and high cell density = 1 cerebella or
cerebra/24 well plate (astrocytes); 1.5× 106 cells/2 cm2 (neurons). Values were determined as a percentage of activity with respect to control cells.
Results are expressed as mean± standard deviation (n= 8 replicates for each cell type in two independent experiments). The letters (a, b, c, and d)
indicate the interaction between origin×MeHg× seeding density for astrocytes and data not showing common letters are signiﬁcantly different
from each other. No signiﬁcant interaction between origin×MeHg× seeding density was observed for neurons. However, please note that all the
MeHg treated cultures differed signiﬁcantly from the control cultures.
(p= 0.035) and MeHg (p= 0.000) as well as signiﬁcant
interactions between the origin×MeHg (p= 0.010) and
cell density×MeHg (p= 0.035) were observed. These
ﬁndings indicated that the cortical neurons were signif-
icantly different from the cerebellar neurons, and low
cell density was signiﬁcantly different from high cell
density. However, no signiﬁcant interaction between ori-
gin×MeHg× cell density was observed for neurons.
4. Discussion
The susceptibility of cells from the cerebrum and
the cerebellum towardsMeHg-induced toxicity has been
compared in very few studies (Mundy and Freudenrich,
2000; Gasso et al., 2001; Adachi and Kunimoto, 2005).
Moreover, these studies have not compared the ability
of cerebellar and cerebral cultures to generate MeHg-
induced ROS with respect to the amount of GSH present
in each of these cultures. Therefore, the present study
explores the role of GSH in exhibiting the differential
effects of MeHg in cerebellar and cortical cultures.
This study corroborates previous studies (Yee and
Choi, 1996; Sanfeliu et al., 2001; Shanker and Aschner,
2003; Shanker et al., 2004, 2005; Kaur et al., 2006) con-
ﬁrming thatMeHg depletes GSH content in both cortical
and cerebellar cultures. It further reports that treatment
with MeHg is associated with greater depletion of GSH
in cerebellar astrocytes, indicating that cortical astro-
cytes are more resistant to MeHg-induced depletion of
GSH. Conversely, cortical astrocytes were more vulner-
able when their GSH content was modiﬁed with NAC
or DEM. This result might be attributed to the pres-
ence of a higher GSH content in cortical astrocytes as
compared to cerebellar astrocytes, as observed in the
present study, possibly indicating that DEM is able to
further deplete the available GSH content, whereas NAC
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is not able to upregulate the already saturated state of
GSH in these cultures. However, non-signiﬁcant inter-
actions between MeHg× pretreatment do not tell us
whether these differences between cortical and cerebel-
lar astrocytes are maintained in NAC or DEM-pretreated
MeHg groups. In neurons, non-signiﬁcant interactions
between origin×MeHg and origin× pretreatment for
GSH indicated that cortical neurons did not vary signif-
icantly from cerebellar neurons for either of the tested
treatments. However, modulation of GSH content with
NAC or DEM pretreatment did signiﬁcantly inﬂuence
the MeHg-induced GSH loss in neurons. This indicates
that an increase in GSH content with NAC pretreatment
prevents MeHg-induced GSH loss in neurons, whereas
a decrease in GSH content with DEM pretreatment aug-
ments this loss.
In accordance with the previous studies (Ali et al.,
1992; Yee and Choi, 1996; Sorg et al., 1998; Saraﬁan,
1999; Sanfeliu et al., 2001; Shanker and Aschner,
2003; Shanker et al., 2004, 2005), the present study
demonstrates that treatment with MeHg induces ROS
in both cerebellar and cortical cultures. It further reports
that modulation of the GSH content inﬂuences MeHg-
induced ROS in these cultures and treatment with MeHg
is associated with greater production of ROS in cere-
bellar cultures. The higher amount of GSH in cortical
astrocytes after exposure to MeHg might explain the
decreased production of ROS in this cell type when
compared to cerebellar astrocytes. However, the non-
differential status of GSH in cortical and cerebellar
neurons after MeHg exposure does not provide an expla-
nation for the increased susceptibility of cerebellar neu-
rons, indicating the importance of factors other thanGSH
in protecting cortical cultures fromMeHg-induced ROS.
The present study reports that cortical neurons were
more sensitive to MeHg-induced cytotoxicity, which is
in accordance with the observation by Miyamoto et al.
(2001). The present study also indicates that NAC alone
is more effective for increasing mitochondrial activity in
cerebellar versus cortical cultures, emphasizing the need
for a better understanding of NAC transporters in vari-
ous brain regions. Moreover, the DEM-pretreated MeHg
group caused a reduction in MTT activity when com-
pared to theMeHggroup, suggesting that, after depletion
of thiol groups by DEM, more MeHg is available for
inhibiting mitochondrial enzymes.
The present study supplements our knowledge
regarding the effects of intracellular GSH concentrations
on cell associated-MeHg.The depletion ofGSHbyDEM
increased the accumulation of MeHg in cell cultures
from both the cerebrum and the cerebellum. The rea-
son for this increased cell associated-MeHg content after
DEM treatment warrants further investigation. Increased
cell associated-MeHg in cerebellar cultures treated with
NAC or DEM might explain the increased vulnerabil-
ity to MeHg toxicity in cerebellar cultures as compared
to cortical cultures. However, previous studies using sil-
ver nitrate, which detects Hg2+ (Leyshon-Sørland et al.,
1994), have postulated that the differential and selective
vulnerability of cells is not simply due to the preferential
accumulation of MeHg since Purkinje cells accumulate
more Hg than granule cells. However, assessment of 14C
labeled-MeHg provides a measurement of the presence
of organic mercury only.
The importance of comparable cell densities for the
studyofMeHg toxicity for comparing different cell types
is of prime importance and appears not to be consid-
ered in previous studies (Mundy and Freudenrich, 2000;
Gatti et al., 2004). The present study reports an increase
in MTT activity in MeHg treated primary cultures of
cerebellar astrocytes when seeded from low to high con-
centrations. Previous studies have reported the effects of
cell density on neuronal survival (Barbin et al., 1984;Dal
et al., 1988) and MTT activity (Erl et al., 2000; Fujita
et al., 2001). Therefore, in cell-based assays, particular
attention should be given to optimal and consistent cell
seeding densities.
Since GSH content only partially explained the dif-
ferential MeHg-sensitivity of cerebellar and cortical
cultures, the role played by other factors should be con-
sidered. Speciﬁc neurotransmitter receptors have been
suggested to contribute to the selective vulnerability of
granule cells (Atchison, 2005). It has been proposed that
MeHg inhibits GABAA receptors and that the presence
of the 6 subunit in cerebellar granule cells (Laurie et
al., 1992; Mathews et al., 1994; Yuan and Atchison,
2003) makes them more vulnerable to MeHg toxicity
than Purkinje cellswhich contain the1 subunit (Wisden
et al., 1992; Puia et al., 1994). Astrocytes express a large
variety of ion channels and neurotransmitter receptors
(Verkhratsky and Steinhauser, 2000). However, cere-
bellar astrocytes do not contain the 6 subunit of the
GABAA receptor (Bovolin et al., 1992), making the
question of the enhanced sensitivity of cerebellar versus
cortical astrocytes even more intriguing. Additionally,
granule cells express the highest density of muscarinic
M3 receptors within the cerebellar cortex (Neustadt et
al., 1988), and downregulation of these receptors has
been reported to protect against MeHg-induced cell
death (Limke et al., 2004). Furthermore, it has been
reported (Basu et al., 2005) that receptors for mus-
carinic acetylcholine (mACh) binding aremore sensitive
in the cerebellum. Another receptor likely to play a role
in distinguishing cell types is the N-methyl-d-aspartate
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receptor (NMDA), since its enhanced sensitivity has
been reported to cause the increased vulnerability of
cortical neurons (Miyamoto et al., 2001). The resistant
Purkinje cells, however, contain AMPA-type receptors
as opposed to the NMDA receptors in the cerebellum.
Alteration of intracellular calcium has been investigated
for comparing the sensitivities of different types of cells
(Denny and Atchison, 1996; Marty and Atchison, 1997;
Mundy and Freudenrich, 2000; Edwards et al., 2005).
Additionally, the inhibition of ryanodine receptors by
MeHg could lead to alterations in calcium signaling,
whichmight be responsible for the sensitivity of cerebel-
lar cultures since the cerebellum contains many of these
types of receptors (Roegge and Schantz, 2006). Iden-
tifying these potentially selective targets during MeHg
poisoning should provide a basis for future research for
determining the mechanism(s) responsible for MeHg
neurotoxicity.
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Abstract
The ability of docosahexaenoic acid (DHA) to modulate methylmercury (MeHg)-
induced neurotoxicity was investigated in primary astrocytes and neurons from the 
cerebellum. Gas chromatography measurements indicated increased DHA content in 
both cell types after 24 hr supplementation. After individual or combined treatment
with MeHg (10µM) and DHA (30 and 90µM), the cell associated-MeHg measurements
were done using 14C-labelled MeHg. In addition, mitochondrial activity was evaluated 
by MTT reduction, glutathione (GSH) content was measured with the fluorescent 
indicator monochlorobimane (MCB) and reactive oxygen species (ROS) were detected 
with the fluorescent indicator -chloro methyl derivative of di-chloro di-hydro 
fluorescein diacetate (CMH2DCFDA). For all the tested treatments i.e. DHA, MeHg or 
DHA + MeHg treatment, the neurons differed significantly (p<0.001) from astrocytes 
exhibiting increased ROS production and decreased MTT activity. After MeHg and 
30µM DHA treatment there were no changes in MTT or GSH content but significant 
decrease (p<0.001) in ROS was observed in both the cell types when compared to 
MeHg alone. The cell associated-MeHg measurements indicated reduced MeHg-
accumulation in both cell types (p<0.05) upon 30µM DHA exposure. Taken together, 
this study, for the first time establishes that DHA pretreatment effectively reduces cell-
associated MeHg and prooxidant response from MeHg in both cerebellar astrocytes and 
neurons and thus supports the hypothesis that fish-derived nutrients offer possible 
neuroprotection from MeHg.
Keywords: Neurotoxicology, In vitro, Primary cell cultures, Glutathione, Reactive 
oxygen species.
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Abbreviations: DHA, Docosahexaenoic acid; MeHg, methylmercury; MTT, [3-(4, 5-
dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide]; GSH, glutathione; MCB, 
monochlorobimane; ROS, reactive oxygen species; CMH2DCFDA, chloro methyl
derivative of di-chloro di-hydro fluoresceindiacetate; PUFA, poly unsaturated fatty 
acids; GFAP, glial fibrillary acidic protein; ALA, Alpha linolenic acid; FAF-BSA,
Fatty acid free bovine serum albumin; DMEM, Dulbecco’s modified eagle’s medium-
low glucose; HEPES, N-2-hydroxy-ethylpiperazine Nƍ-2-ethansulfonic acid; BSA, 
bovine serum albumin; FCS, fetal calf serum; GC, gas chromatography; LA, linoleic 
acid; DPA, docosapentaenoic acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; 
GPx, glutathione peroxidase .
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1. Introduction
Methylmercury (MeHg) is an important environmental neurotoxicant that affects the 
developing and mature nervous system (Atchison, 2005; Clarkson et al., 1988). The 
major dietary route of human exposure to MeHg is via the ingestion of seafood for 
adults (Clarkson, 1997; Kamps et al., 1972; Spry and Wiener, 1991) and via maternal
milk for infants (Franco et al., 2006; Manfroi et al., 2004). MeHg causes a reduction in 
intracellular glutathione (GSH) (Choi et al., 1996; Miura and Clarkson, 1993; Sarafian 
et al., 1994). Previous work from our laboratory (Kaur et al., 2007b) reported that the 
B35 neuronal cell line responded to MeHg by increasing GSH levels, an effect that was
opposite to what had been reported for in situ primary neurons (Sanfeliu et al., 2001). 
Since cerebellum is the major target organ of MeHg exposure which is accompanied
with the loss of granule cell layer (Eto and Takeuchi, 1978; Vendrell et al., 2007); 
neural cells from cerebellum were selected for the present study as a cellular model for
studying MeHg-induced neurotoxicity.
The nervous system is highly enriched in long-chain poly unsaturated fatty acids 
(PUFAs). Fish and maternal milk are the major dietary sources of PUFAs (Larque et 
al., 2002; Rodriguez et al., 1999). Docosahexaenoic acid (DHA; 22:6n-3), in particular, 
is the most abundant polyunsaturated fatty acid in the brain and it is essential for the 
normal brain function (Kim, 2007; Salem et al., 1999; Uauy et al., 2001). Accretion of 
DHA in the central nervous system occurs actively during the developmental period 
(Scott and Bazan, 1989). DHA can be biosynthesized from alpha-linolenic acid (ALA) 
through chain elongation and desaturation processes (Sprecher, 2000). While neurons 
are highly enriched with DHA, they cannot produce it because of lack of desaturase 
activity; only astrocytes have the capacity to synthesize DHA (Moore et al., 1991). 
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Astrocytes are in close contact with neurons and readily release DHA into the 
extracellular fluid under basal and stimulated conditions, thus providing a source for 
neuronal DHA (Garcia and Kim, 1997; Kim et al., 1999; Moore, 2001). Considering 
astroglia support neurons by providing neurotrophic factors, the supply of DHA by 
astrocytes can also be trophic.
MeHg has been reported to augment reactive oxygen species (ROS) formation (Ali et
al., 1992; Gasso et al., 2001; Sanfeliu et al., 2001; Sarafian, 1999; Shanker and 
Aschner, 2003; Sorg et al., 1998; Stringari et al., 2008; Yee and Choi, 1996). However, 
the ability of DHA to induce ROS is controversial. Several contrasting studies 
documenting the apoptotic (Albino et al., 2000; Chen and Istfan, 2000; Diep et al., 
2000) and antiapoptotic (Akbar and Kim, 2002; Kim et al., 2000; Kishida et al., 1998; 
Rotstein et al., 1997; Yano et al., 2000) effects of DHA have been reported. In addition, 
contrary to the ability of DHA to decrease the level of lipid peroxide (Gamoh et al., 
1999; Hashimoto et al., 2002, 2005); it has also been reported to cause free radical-
mediated peroxidation in the brain (Leonardi et al., 2005; Montuschi et al., 2004; Tsai 
et al., 1998). Therefore, it is of importance to ascertain whether the balance between the 
oxidative and reductive cellular processes is disturbed following combined exposure to 
DHA and MeHg (DHA + MeHg). 
The current advice on human mercury contaminated seafood intake is based on 
population data where the primary source of MeHg is either fish diet (Davidson et al., 
1998; Harada, 1995; Myers et al., 1997), combined fish and whale meat diet (Grandjean 
et al., 1997) or wheat (Bakir et al., 1973). In particular the Seychelles (Myers et al.,
1997) and the Faroes (Grandjean et al., 1997) studies differ with respect to possible 
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neurodevelopmental effects of MeHg exposure. The sources for these differences in the 
above mentioned studies have not been clearly identified (CENR, OSTP and The White
house, 1998). The risk evaluation of the combined exposure to a neurotoxicant and 
neuroprotectant remains unsettled. Therefore, it is important to assess dietary nutrients 
as well as neurotoxic exposures in determining the risks and benefits of fish 
consumption (Myers et al., 2007). Our aim has been to provide an experimental
rationale for the possible neuroprotective components present in the fish diet. Our 
findings contribute to a better understanding on the neurodevelopmental discrepancies 
found in the Seychelles (Davidson et al., 1998) and Faroes studies (Grandjean et al., 
1997).
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2. Materials and methods 
2.1. Materials 
24-well plastic tissue culture plates were purchased from Falcon (Becton Dickinson 
Labware, USA). Fetal bovine serum (Cat. No. 04-007-1A) used for cerebellar 
cultures was purchased from Biological Industries, In Vitro AS (Denmark). The 
culture medium (Cat. No. D5030) was acquired from Sigma Aldrich (Germany).
Fatty acid free bovine serum albumin (FAF-BSA, Cat. No. A0281), DHA (Cat. No. 
D2534), MCB (Cat. No. 69899), MTT (Cat. No. M2128) and Poly-D-Lysine (Cat. 
No. P1024) were purchased from Sigma Aldrich (Norway). The fluorescent indicator 
CMH2DCFDA (Cat. No. C6827) was purchased from Molecular Probes, Inc. 
(Eugene, OR, USA). Radiolabeled 14C-MeHg (Cat. no. ARC-1302) was purchased 
from American Radiolabeled Chemicals Inc. (St. Louis, MO, USA). MeHgCl which 
was 99% pure (Cat. No. 23308) was purchased from K&K Laboratories (Plainview, 
NY, USA). All other chemicals were of analytical grade.
2.2. Animals 
NMRI mice were purchased from Møllegaard Breeding Center (Copenhagen, 
Denmark). The animals had free access to food and water and were kept under the 
following constant conditions: temperature (22°C), humidity (60%) and 12 hr 
light/dark cycles. The animals were handled in compliance with the NTNU Animal
Care and Use Committee.
2.3. Cell cultures 
Primary cultures of cerebellar astrocytes were prepared from 7-day-old mice as 
described earlier (Hertz et al., 1989). Briefly, cerebella obtained from the brains of 
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mice were directly passed through Nitex nylon netting (80 µm pore size) into DMEM 
containing 20% (v/v) fetal calf serum (FCS). The cell suspension was then plated at a 
density of 1 cerebellum per 24-well culture plate, which was coated previously with 
poly-D-lysine. The medium was changed two days after plating and subsequently 
twice a week, gradually decreasing the FCS concentration to 10%. At 14 days in 
culture, dibutyryl-cAMP was added to the medium for one week to promote the 
morphological differentiation of astrocytes. The cerebellar astrocytes multiply during
this period and were used for the experiment 21 days post isolation.
Primary cultures of cerebellar neurons were prepared from 7-day-old mice according to 
the method described by (Schousboe et al., 1989). Briefly, mild trypsinized cerebella
were triturated in a DNase solution containing a soybean trypsin inhibitor. The cells 
were suspended in DMEM (19 mM KCl, 31 mM glucose, and 0.2 mM glutamine)
supplemented with p-aminobenzoate, insulin, penicillin, garamycin and 10% (v/v) FCS. 
Cells were seeded at a density of 1.5×106 cells/2cm2 in 24-multiwell plates, which were 
previously coated with poly-D-lysine. The cell were then incubated in a humidified 5% 
CO2 / 95% air atmosphere at 37°C and used one week post isolation as previously 
described (Kaur et al., 2007a). 
2.4. Cell culture and DHA modification 
Cell morphology was frequently checked using phase contrast microscopy. A stock 
solution of 630 and 1890µM DHA was prepared in media with FFA-BSA and was 
used to modify the fatty acid content of the primary cells (shown in Table 2 and 3). 
The stock solution was added directly to the cells such that the final concentration
given to the cells was 30 and 90µM DHA. The control cells received the same
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amount of normal media with FFA-BSA. The cerebellar astrocytes and neurons 
received DHA on day twenty and seven respectively; and were then used for the 
experiment on day twenty one and eight i.e. 24 hrs after incubation with DHA. The 
concentrations of DHA were identical to those used in the previous study in cell lines 
(Kaur et al., 2007b) as a major aim of this study is to compare those effects in 
primary cells. The amount of protein present at the day of the experiment was 
between 100-125 µg protein per well for both cerebellar astrocytes and neurons. The 
seeding density was chosen to facilitate the fluorescence measurements.
2.5. Treatments 
A stock solution of 1mM MeHgCl was prepared in 5mM Na2CO3. From this stock, a 
working solution was prepared in HEPES buffer [122 mM NaCl, 3.3 mM KCl, 0.4 
mM MgSO4.7H2O, 1.3 mM CaCl2, 1.2 mM KH2PO4, 10 mM glucose and 25 mM
HEPES adjusted to pH 7.4 with 10 N NaOH]. On the day of the experiment, the cells 
were washed once with HEPES buffer and incubated with 10µM MeHg for 50 min.
For the last 20 min, the cells were incubated with either fluorescent probes 
CMH2DCFDA (7µM) or MCB (40µM) or with colorimetric reagent MTT (2.4mM).
We selected the same MeHg concentration for a short exposure time since we wanted 
to compare the effects in primary cells as opposed to the previously used cell lines 
(Kaur et al., 2007b).
2.6. Determination of fatty acid content in media and primary cells 
Fatty acid composition of total lipids was analyzed by using a Trace Gas 
Chromatography (GC) Ultra gas chromatograph (Thermo Electron Corporation, 
Waltham Massachusetts, USA) with a Merlin microseal septumless SSL injector. The
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gradient temperature program started at 100°C, rising to 220°C (at 50°C/min), holding 
220°C for 1 minute then rising to 250°C (at 80°C/min), then holding for 1.5 minutes.
The GC was equipped with a Thermo UFM Ultrafast wax column (length: 5 m, id: 
0.1 mm). Lipids from the samples were extracted and then saponified and methylated
with NaOH and BF3 (both in methanol) under heat, respectively. Fatty acids were 
detected by Flame Ionization Dectector and identified by retention time using standard 
mixtures of methyl esters (Nu-Chek, Elyian, USA), and then quantified using 
Chromeleon software (version 6.80, Dionex). The amount of fatty acid per weight of 
the tissue or media was calculated using 19:0 methyl ester as an internal standard.
2.7. Determination of free thiol levels 
The content of intracellular free thiols was determined by using the fluorescent
indicator, MCB (40µM) as described previously (Kaur et al., 2006, 2007a). The final 
values of fluorescence were corrected for intracellular protein in each well and 
expressed as a percent of fluorescence in control wells. 
2.8. Detection of intracellular ROS accumulation 
Intracellular ROS accumulation was monitored as described previously (Kaur et al., 
2006, 2007a) using CMH2DCFDA (7µM) which upon oxidation yields a fluorescent 
adduct dichloro fluorescein (DCF). The final values were corrected for intracellular 
protein in each well and expressed as a percent of fluorescence in control wells. 
2.9. Cytotoxicity activity 
Cytotoxicity was determined by colorimetric MTT (2.4mM) reduction assay 
(Carmichael et al., 1987; Dahlin et al., 1999) by measuring the absorbance obtained 
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at 570 nm using a Sunrise absorbance reader (Tecan, Austria). Cytotoxicity was then 
expressed as a percent of MTT activity in control wells. 
2.10. Cellular MeHg accumulation 
The cell associated-MeHg studies were done with 14C-labeled 10µM MeHg (82 
nCi/µg Hg) for 50 min as described previously (Kaur et al., 2007a,b). The 
radioactivity in cells was counted in a 1450 Micro Beta Trilux Liquid scintillation 
counter (Wallac, Perkin Elmer Life Sciences, Norway) and corrected for cellular 
protein.
2.11. Estimation of protein
Protein concentration was determined by the folin reagent with BSA as a standard 
(Lowry et al., 1951). 
2.12. Data analysis 
All results are given as mean ± standard deviation. Differences between groups were 
analyzed statistically with one-way ANOVA followed by the Tukey HSD post hoc
test for multiple comparisons and p<0.05 was considered statistically significant. In 
addition, a three-way ANOVA was done to evaluate the interactive effects between 
different parameters. Cell type (cerebellar astrocytes or neurons), MeHg treatment
and DHA pretreatment were considered as three fixed factors for the dependent 
variables, DCF, MCB and MTT. For the dependent variable, fatty acids, cell type, 
type of fatty acid and DHA pretreatment were considered as three fixed factors. The 
three-way ANOVA was done according to the SPSS Base 14.0 User’s Guide, GLM 
Univariate Analysis.
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3. Results
The interactive effect between cell type, MeHg treatment and DHA pretreatment for 
primary cells is shown in Table 1. For both cell types, a significant interactive effect
(p=0.000) between all three parameters was noted for the dependent variables ROS 
and MTT. This indicates that neurons differed significantly from astrocytes 
exhibiting increased ROS and decreased MTT activity after DHA, MeHg or DHA + 
MeHg treatment. For the dependent variable GSH, a significant interactive effect 
between cell type and DHA pretreatment, as well as cell type and MeHg treatment
was noted. Observation under the microscope indicated that treatment with DHA for 
24 hrs did not induce any morphological changes in the cells. 
3.1. Modification of fatty acids by treatment with DHA
The fatty acid composition for the incubation media and for the primary cells is 
shown in Tables 2 and 3, respectively. The significant interaction between type of 
fatty acid × DHA pretreatment in the incubation media and primary cells (Table 1) 
indicated that pretreatment with DHA for 24 hrs resulted in a concentration-
dependent cellular uptake of DHA from the incubation media. In addition, significant 
interaction between the effect of cell type × type of fatty acid in primary cells 
indicated that astrocytes varied significantly and had increased fatty acid content as 
compared to neurons. However, the non-significant interaction between the cell type 
× type of fatty acid × DHA pretreatment in the media and cells (Table 1) indicated 
that the DHA content in media used for pretreatment and the DHA content in cells 
after pretreatment was similar for both astrocytes and neurons. The incubation media
(Table 2) contained the majority of DHA with small amounts of other PUFAs, such 
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as linoleic acid (LA) and ALA. However, the levels of LA and ALA in the incubation 
media did not vary significantly between the control, 630 and 1890 µM DHA media.
The cerebellar astrocytes treated with DHA (Table 3) varied significantly (p<0.05) 
from the cerebellar neurons in the levels of total, sum of identified, DPA 
(docosapentaenoic acid), AA (arachidonic acid), LA, ALA, stearic and palmitic fatty 
acids. Furthermore, the level of DHA, AA and EPA (eicosapentaenoic acid) were 
also modified in cerebellar astrocytes after 90µM DHA treatment when compared to 
the control group. The increase of DHA in cerebellar astrocytes was associated with 
an increase in EPA and decrease in AA. After DHA treatment, the ratio of DHA/AA 
increased significantly (p<0.001) in astrocytes and neurons, the most prominent
increase being observed in the neurons.
3.2. Modification of mitochondrial activity by treatment with MeHg and DHA
Exposure to MeHg (10µM) resulted in a more pronounced reduction of MTT activity 
in cerebellar neurons as compared to cerebellar astrocytes (Fig. 1). For the dependent 
variable, MTT, significant interactions for all the tested parameters were observed 
(Table 1), indicating that cerebellar neurons exhibited a greater reduction in MTT 
activity at all the tested treatments and differed significantly from the cerebellar 
astrocytes. In cerebellar astrocytes a significant increase (p<0.05) in MTT activity 
was observed after 30 and 90µM DHA treatment. On the other hand, the cerebellar 
neurons treated with 90µM DHA, exhibited a reduction in mitochondrial activity 
(p<0.001) when compared to control group. For both astrocytes and neurons treated 
with 30µM DHA + MeHg, no further reduction in MTT activity was observed when 
compared to MeHg group. Only in cerebellar neurons treated with 90µM DHA + 
13
MeHg, a greater reduction in mitochondrial activity (p<0.001) was observed when 
compared with MeHg alone.
3.3. Modification of cellular thiols by treatment with MeHg and DHA
The GSH levels in cerebellar astrocytes and neurons were quantified with 
fluorescence intensity measurements of the bimane-GSH adduct (Fig. 2). The 
significant interactions for the dependent variable GSH (Table 1) indicated that 
cerebellar astrocytes varied significantly from the cerebellar neurons after MeHg 
treatment (cell type × MeHg p=0.000) and DHA pretreatment (cell type × DHA 
pretreatment p=0.000). Treatment with DHA alone induced a reduction in GSH 
activity (p<0.001) only in cerebellar neurons at 90µM dose when compared to control 
group. Additionally, 90µM DHA + MeHg treatment was able to further reduce the 
GSH content in cerebellar neurons when compared with MeHg alone (p<0.001). 
However, the cerebellar neurons at 30µM DHA and cerebellar astrocytes at both 30 
and 90µM DHA did not exhibit this trend of decreased GSH content after combined
DHA + MeHg treatment as compared to the group treated with MeHg only.
3.4. Depletion of GSH content induces ROS generation 
ROS levels in primary cultures quantified by the fluorescence intensity of the 
oxidized product, DCF, are shown in Fig. 3. A significant interaction between cell 
type × MeHg × pretreatment (Table 1) indicated that the amount of ROS produced in 
cerebellar astrocytes varied significantly (p=0.000) from the cerebellar neurons. The 
cerebellar neurons, when treated with MeHg alone or MeHg + DHA, exhibited
increased production of ROS (p<0.001) as compared to cerebellar astrocytes. In the 
cerebellar neurons, treatment with 90µM DHA alone resulted in induction of ROS 
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(p<0.05). However, after DHA + MeHg exposure there was a decrease in ROS 
production in cerebellar neurons (p<0.001) when compared to MeHg treated group. 
In addition, the amount of ROS produced in cerebellar astrocytes in the DHA + 
MeHg treated group did not vary significantly from the control group. The DHA + 
MeHg treatment resulted in 60% decrease in ROS in cerebellar neurons (p<0.001) as 
compared to 30% decrease in cerebellar astrocytes when compared to MeHg treated 
group.
3.5. DHA modulation affects cell associated-MeHg 
In both the cell types, treatment with 30µM DHA led to significant (p<0.05) decrease 
in cell-associated MeHg when compared to MeHg treated group (Table 4). The 90µM 
DHA concentration resulted in decreased cell-associated MeHg only in cerebellar 
neurons. In both cell types, the 30 and 90µM DHA treated groups did not vary 
significantly from each other with respect to the cell-associated MeHg. The cerebellar
astrocytes varied significantly (p<0.001) and exhibited decreased cell-associated 
MeHg when compared to cerebellar neurons for all the tested treatments.
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4. Discussion
Dietary exposure to MeHg has been linked to adverse neurological effects and is a 
public health concern particularly among fish-eating populations (Crump et al., 1998; 
Grandjean et al., 1997; Kjellstrom et al., 1989). However, findings by Hibbeln et al. 
(2007), using the Avon Longitudinal Study of Parents and Children (ALSPAC), 
indicated that lower intake of seafood during pregnancy is associated with higher risk 
of suboptimal neurodevelopmental outcomes. In addition, studies at Seychelles 
(Davidson et al., 1998; Myers et al., 1997), Peru (Marsh et al., 1995) and US 
(Mozaffarian and Rimm, 2006; Oken et al., 2005) have also indicated possible 
opposing effects of overall fish consumption (i.e., providing DHA) and MeHg 
exposure. These studies have raised the question of the rationale behind the decision of 
FDA’s fish advisories (US EPA and FDA, 2004) to limit seafood consumption. 
Therefore, more studies aimed at analyzing the combined effects of MeHg and DHA 
exposure are necessitated. The innovative aspect of this study is the analysis of effects 
inherent to each of these compounds individually or when simultaneously administered
to primary neural cells. Overall, the present study clearly establishes the ability of DHA 
to afford reduction towards normalization of MeHg-induced ROS. 
Previous work from this laboratory (Kaur et al., 2007b) reported increased MeHg-
induced ROS after DHA pretreatment using C6-glial and B35-neuronal cells. It was 
reported that C6-glial cells had increased sensitivity towards MeHg and DHA-
induced oxidative stress as compared to the B35-neuronal cells. However, it has been 
well known that astrocytes contain higher concentrations of GSH than neurons 
(Kranich et al., 1996), and GSH provides a major cellular defense against MeHg-
induced ROS (Yee and Choi, 1996). In addition, the rate limiting precursor for GSH 
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synthesis, cysteine, is provided by astrocytes to neurons for the neuronal synthesis of 
GSH (Kranich et al., 1998; Sagara et al., 1993; Wang and Cynader, 2000). Therefore, 
the previously reported results on increased GSH content in B35 cells upon MeHg 
exposure was contrary to other observations from a range of neuronal models. This 
observation warranted a study using primary cells to provide a better understanding 
and characterization of the effects of DHA and MeHg treatment.
The present study reports that MTT activity in cerebellar neurons was attenuated to a 
greater degree at all the experimental conditions when compared to astrocytes. This 
indicates that mitochondrial dehydrogenase enzyme is inhibited more significantly in 
cerebellar neurons after MeHg exposure as compared to astrocytes, which is in 
accordance with other studies (Morken et al., 2005; Sanfeliu et al., 2001). In addition, 
the well documented effects of MeHg-induced GSH depletion (Carty and Malone, 
1979; Hughes, 1957; Mokrzan et al., 1995) and ROS generation (Sanfeliu et al., 
2001; Sorg et al., 1998) were corroborated by cerebellar neurons and astrocytes 
where neurons exhibit more pronounced GSH depletion and ROS production.
The relationship between DHA levels and oxidative stress remains controversial. It 
has been reported that DHA enrichment either increases (Song et al., 2000; Brand et 
al., 2000) or decreases (Bechoua et al., 1999; Yavin et al., 2002) sensitivity to free 
radicals. Moreover, the combined effects of DHA and MeHg exposure on ROS levels 
have not been investigated in primary neural cells. Here, we note that combined
exposure to DHA and MeHg was effective in attenuating MeHg’s effect alone, 
reducing ROS levels in cerebellar astrocytes to levels indistinguishable from controls. 
Similar effects were seen in cerebellar neurons, where treatment with DHA and 
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MeHg significantly reduced ROS levels in comparison to MeHg treatment alone. The 
ability of DHA to reduce the ROS levels in primary cells is contrary to our results in 
transformed cell lines (Kaur et al., 2007b). It has been previously reported 
(Grammatikos et al., 1994; Tsai et al., 1998) that the growth of cancerous cells is 
more significantly inhibited by DHA as compared to non-cancerous cell type. They 
also reported that the cellular response to exogenous long-chain PUFAs is modified
during the course of malignant transformation. Therefore the choice of cellular model
for studying the effects of DHA is critical. 
The reduced ROS levels after DHA + MeHg exposure in cerebellar astrocytes and 
neurons did not induce any significant changes in MTT or GSH production when 
compared with MeHg alone. Only in neurons at 90µM DHA concentration, there was 
a significant reduction in MTT activity and GSH content which was associated with 
increased ROS production. However after combined exposure to 90µM DHA and 
MeHg, there was no further increase in ROS in this group. This could be due to the 
presence of higher DHA/AA ratio in neurons as compared to astrocytes. It has been 
reported that a higher DHA/AA ratio prevents the generation of lipid peroxides 
(Gamoh et al., 1999; Hashimoto et al., 2005). In addition, it has been reported that 
toxicity of DHA is due to decrease in glutathione peroxidase (GPx) levels (Ding and 
Lind, 2007). Therefore, the protective effects of DHA against MeHg-induced ROS 
could be due to increased GPx levels, which, in turn, could lead to disposal of 
exogenous peroxides by conversion of reduced GSH to the oxidized form, GSSG 
(Eklow et al., 1984; Wendel, 1980). Since, the fluorescent compound MCB has been 
reported to react with the reduced form of GSH (Haugland, 1996), the decreased 
GSH and ROS levels might be explained by the increased activity of GPx by DHA.
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We further noted a concentration-dependent accumulation of DHA in both primary
neurons and astrocytes. However, the total lipid content of the primary cells was not 
modified after exposure to 30 and 90µM DHA. The concentration of DHA in adult 
rat brain and retina has been reported to range from 17% to >33% of the weight of the 
total fatty acids (Hamano et al., 1996; Stubbs and Smith, 1984). In the present study, 
DHA treatment resulted in DHA constituting 24-41% of the total fatty acids in the 
primary cultures. The amount of mg DHA/gm test material in primary cells is similar
to the levels previously reported in cell lines (Kaur et al., 2007b). Apart from DHA, 
the cerebellar astrocytes varied significantly from the cerebellar neurons in the 
content of total, sum of identified, DPA, AA, EPA, LA, ALA, stearic and palmitic
fatty acids. In general, astrocytes had higher fatty acid content than neurons in all the 
tested groups. These differences can be attributed to the supporting role played by 
astrocytes and the dependence of neurons on long-chain PUFA’s derived from
neighboring astrocytes (Moore et al., 1990; Spector and Moore, 1992).
Our results show that DHA treatment was associated with an increase in EPA and 
decrease in AA, probably due to reverse metabolism (retroconversion) of DHA to 
EPA leading to a compensatory decrease in AA which is in accordance with the
previous reports in astrocytes (Champeil-Potokar et al., 2004, 2006) and other cell 
types (Alessandri et al., 2003). Since MeHg has been reported to increase the release 
of AA (Shanker et al., 2002), decrease in AA levels with DHA could be one of the 
mechanisms behind the protective effects of DHA. Moreover, the increase in AA 
metabolites is intimately integrated with decrease in GPx activity (Bryant et al., 1982;
Vericel et al., 1992; Weitzel and Wendel, 1993). This phenomenon further 
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strengthens our proposed mechanism of increased GPx activity behind decreased 
GSH and ROS levels in 90µM DHA + MeHg treated cerebellar neurons.
The same 10µM MeHg concentration for a short exposure time (50min) was selected 
in order to compare the effects in primary cells to the previously used cell lines (Kaur 
et al., 2007b). The MeHg content observed in the present study is 10-20 times that of 
in vivo studies (Eto, et al., 2001) or same as in extended in vitro exposure studies 
(Sakaue et al., 2006) since the effective dose during in vitro exposure must be 
considerable higher than the in vivo situation when the target concentration is used as 
a dose indicator. Exposure to 10µM MeHg for a 50min period resulted in Hg levels in 
primary astrocytes analogous to the levels observed in the C6-glial cell line (Kaur et 
al., 2007b). However, the Hg levels found in primary neurons were higher than the 
levels found in B35-neuronal cell line (Kaur et al., 2007b). This may explain the 
increased cytotoxicity in primary neurons to MeHg vs. B35 cells. In the present 
study, DHA treatment led to reduced cell associated-MeHg in neurons at both 30µM 
and 90µM dose and in astrocytes at 30µM dose. The reduced cell associated-MeHg in 
astrocytes and neurons correlates with the protective effect of DHA against MeHg-
induced ROS.
Primary neurons accumulated more MeHg than astrocytes, which is in accordance 
with our previous reports (Kaur et al., 2006, 2007a). However, previous studies using 
silver nitrate have reported that MeHg accumulates preferentially in astrocytes rather 
than in neurons (Leyshon-Sørland et al., 1994). The possible explanation for this 
discrepancy is that silver nitrate technique detects Hg2+ whereas the assessment of 14C
labeled-MeHg provides a measurement of organic mercury only.
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In summary, the DHA pretreatment reduced the cell-associated MeHg and prooxidant 
response from MeHg challenge in primary cells. This was not associated with an 
increase in MTT activity or GSH content. The protection afforded against ROS in 
DHA + MeHg treated group could be due to production of less ROS due to reduced 
cell-associated or intracellular MeHg. The proposed protective mechanisms against 
MeHg-induced ROS may include the reduction in AA levels and increase in GPx 
activity which may further influence the downstream transcription factors and signal 
transduction pathways. Recognition of these protective effects and identification of
their mechanisms may improve the basis for risk/benefit assessment of a MeHg-
containing fish diet.
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TABLE 1. 
F and P values calculated with three-way ANOVA for interactive effects between cell 
type (cerebellar astrocytes or neurons), MeHg treatment and DHA pretreatment for 
different parameters investigated in primary astrocytes and neurons from the
cerebellum. N.S. indicates not statistically significant effect. 
Interactions GSH ROS MTT
Effect of cell type × MeHg F=49.249P=0.000
F=136.795
P=0.000
F=4.271
P=0.041
Effect of cell type × DHA pretreatment F=11.158P=0.000
F=1.630
P=0.200
F=45.274
P=0.000
Effect of MeHg × DHA pretreatment F=1.385P=0.256
F=33.607
P=0.000
F=3.811
P=0.025
Effect of cell type × MeHg × DHA 
pretreatment
F=2.878
P=0.062
F=8.554
P=0.000
F=12.247
P=0.000
Interactions Fatty Acids-media Fatty Acids-cells
Effect of cell type × type of fatty acid N.S.
F=6.260
P=0.000
Effect of cell type × DHA pretreatment N.S. N.S.
Effect of type of fatty acid × DHA 
pretreatment
F=219.498
P=0.000
F=4.942
P=0.000
Effect of cell type × type of fatty acid × DHA 
pretreatment
N.S. N.S.
36
TABLE 2. Fatty acid composition in the media after DHA treatment as measured by 
GC. N.D. indicates not detectable. 
Incubation Media Fatty Acids Control 630µM DHA 1890µM DHA 
Total Fatty Acids 26.0 ± 9.3 221.4 ± 5.7 a 622.4 ± 27.4 a b
Fatty Acids Identified 24.7 ± 8.6 215.4 ± 12.1 a 625.8 ± 25.9 a b
DHA (22:6n-3) N.D. 192.0 ± 17.9 584.1 ± 51.1 b
LA (18:2n-6) 2.4 ± 1.1 1.7 ± 0.6 1.5 ± 0.5 
Ast-DMEM
(Cerebellar
astrocytes)
Į linoleic (18:3n-3) 2.0 ± 0.4 2.3 ± 0.8 2.7 ± 0.4
Total Fatty Acids 19.6 ± 9.8 237.4 ± 37.3 a 659.3 ± 94.8 a b
Fatty Acids Identified 18.5 ± 8.9 235.9 ± 36.3 a 652.7 ± 100.1 a b
DHA (22:6n-3) N.D. 213.0 ± 24.8 617.7 ± 87.1 b
LA (18:2n-6) N.D. 1.8 ± 0.8 1.5 ± 0.4 
N-DMEM
(Cerebellar
neurons)
Į linoleic (18:3n-3) 2.4 ± 0.3 2.5 ± 0.3 2.9 ± 0.8
Values are expressed as mean ± standard deviation (µg fatty acids/gm test material).
Experiments were conducted in 4 replications for each cell types. The superscript (a)
indicates p<0.05 as compared to control group; (b) indicates p<0.05 as compared to 
630µM DHA treated group.
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TABLE 3. Fatty acid composition in the cells after DHA pretreatment as measured
by GC. N.D. indicates not detectable.
Primary Cells Fatty Acids Control 30µM DHA 90µM DHA 
Total Fatty Acids 2.3 ± 0.7 c 2.8 ± 0.7 c 3.3 ± 1.1 c
Fatty Acids 
Identified
2.1 ± 0.6 c 2.3 ± 0.6 c 3.2 ± 1.2 c
DHA (22:6n-3) 0.16 ± 0.02 0.68 ± 0.2 a 1.3 ± 0.2 a b
DPA (22:5n-3) 0.1 ± 0.03 c 0.1 ± 0.03 c 0.1 ± 0.04 c
AA (20:4n-6) 0.37 ± 0.04 c 0.30 ± 0.08 c 0.20 ± 0.08 a c
EPA (20:5n-3) 0.02 ± 0.01 0.05 ± 0.02 0.06 ± 0.02 a
LA (18:2n-6) 0.03 ± 0.01 0.03 ± 0.01 c 0.03 ± 0.02 c
Į linoleic (18:3n-3) 0.01 ± 0.005 c 0.01 ± 0.002 c 0.01 ± 0.002 c
Stearic (18:0) 0.4 ± 0.07 c 0.5 ± 0.03 c 0.5 ± 0.14 c
Palmitic (16:0) 0.5 ± 0.1 c 0.6 ± 0.2 c 0.7 ± 0.1 c
Cerebellar
Astrocytes
DHA/AA ratio 0.43 ± 0.05 c 2.27 ± 1.25 a c 6.5 ± 1.52 a b c
Total Fatty Acids 0.9 ± 0.2 1.6 ± 0.7 2.6 ± 0.8 
Fatty Acids 
Identified
0.8 ± 0.1 1.5 ± 0.7 2.4 ± 0.7 
DHA (22:6n-3) 0.1 ± 0.02 0.47 ± 0.1 a 1.05 ± 0.3 a b
DPA (22:5n-3) 0.02 ± 0.007 0.03 ± 0.01 0.03 ± 0.01 
AA (20:4n-6) 0.08 ± 0.03 0.08 ± 0.02 0.10 ± 0.01 
EPA (20:5n-3) N.D. N.D. N.D.
LA (18:2n-6) 0.009 ± 0.0004 0.011 ± 0.009 0.014 ± 0.006 
Į linoleic (18:3n-3) 0.004 ± 0.0007 0.004 ± 0.0005 0.006 ± 0.001 
Stearic (18:0) 0.3 ± 0.01 0.3 ± 0.09 0.3 ± 0.05 
Palmitic (16:0) 0.1 ± 0.04 0.1 ± 0.07 0.2 ± 0.14 
Cerebellar
Neurons
DHA/AA ratio 1.25 ± 0.22 5.88 ± 0.54 a 10.5 ± 1.83 a b
Values are expressed as mean ± standard deviation (mg fatty acids/gm test material).
Experiments were conducted in 4 replications for each cell types. The superscript (a) 
indicates p<0.05 as compared to control group; (b) indicates p<0.05 as compared to 
30µM DHA treated group; (c) indicates p<0.05 when astrocyte v/s neurons for each 
type of treatment.
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TABLE 4. 
Effect of DHA on MeHg accumulation in cerebellar astrocytes and neurons as 
measured by 14C radiolabeled MeHg at 50 min.
Cell Line 10µM MeHg 30µM DHA + MeHg 90µM DHA + MeHg 
Cerebellar astrocytes 2.9 ± 0.2 c 2.5 ± 0.2 a c 2.6 ± 0.2 c
Cerebellar neurons 4.6 ± 0.3 4.1 ± 0.2 a 4.1 ± 0.2 a
Values are expressed mean ± standard deviation (µg Hg/mg protein). Experiments
were conducted in 10 replications for each cell types in two independent experiments.
The superscript (a) indicates p<0.05 as compared to only MeHg treated group; (c)
indicates p<0.05 when astrocytes v/s neurons for each type of treatment. Values were 
corrected for protein content in each well.
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Cellular GSH detected by MCB fluorescence in primary cells
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Cellular ROS detected by CMH2DCFDA fluorescence in primary cells
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Legends
FIG. 1. Cytotoxicity detected by reduction of MTT in cerebellar astrocytes and
neurons. Results are expressed as mean ± standard deviation (n=8 replicates for each
cell type in two independent experiments). The superscript (*) indicates p<0.05 as 
compared to control group; (#) indicates p<0.05 when astrocytes v/s neurons for each 
type of treatment; (§) indicates p<0.05 where MeHg v/s (DHA + MeHg) treated 
group. Values are presented as a percentage of activity in control cells.
FIG. 2. Cellular GSH detected by MCB fluorescence in cerebellar astrocytes and
neurons. Results are expressed as mean ± standard deviation (n=8 replicates for each
cell type in two independent experiments). The superscript (*) indicates p<0.05 as 
compared to control group; (#) indicates p<0.05 when astrocytes v/s neurons for each 
type of treatment; (§) indicates p<0.05 where MeHg v/s (DHA + MeHg) treated 
group. Values were corrected for protein content in each well and determined as a
percentage of fluorescence with respect to control cells. The average control
fluorescence units for cerebellar astrocytes are 29764 ± 283 and for cerebellar 
neurons are 19982 ± 1368.
FIG. 3. Cellular ROS detected by CMH2DCFDA fluorescence in cerebellar 
astrocytes and neurons. Results are expressed as mean ± standard deviation (n=8 
replicates for each cell type in two independent experiments). The superscript (*)
indicates p<0.05 as compared to control group; (#) indicates p<0.05 when astrocytes 
v/s neurons for each type of treatment; (§) indicates p<0.05 where MeHg v/s (DHA + 
MeHg) treated group. Values were corrected for protein content in each well and 
determined as a percentage of fluorescence with respect to control cells.
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